2012 annual report we are living at an extraordinary moment.

building on amazing technologies that took decades to develop, lls is helping to make and further discoveries that will provide every blood cancer patient with safe and effective therapy.

the years people have invested in us and the funds they continue to raise are bringing healing therapies once thought impossible.

simply put, we are closer than ever to the cures for many kinds of blood cancers. we are on the brink of historic breakthroughs that will literally change people’s lives.

because of our work, blood cancers will never be the same. the leukemia & lymphoma society today 2 president & chairman’s message

When people talk about cancer they often use hopeful words like “someday:” Someday a cure will be found. It is a wonderful shock to realize that today we find ourselves in that someday. As a result of our 60 plus years of investing in new cancer treatments, our productive approach to venture philanthropy, and the breathtaking achievements coming out of our Therapy Acceleration Program™ (TAP), the treatments LLS has supported and helped bring to market are bearing fruit: We are saving more lives. And we are saving them faster than ever before.

That is why we are proud to declare this new expression of our commitment: Someday is today. We are having a profound effect on the way blood cancers impact our lives. Read through John E. Walter this report and you will be astonished by the breakthroughs we have made and the ones we President & CEO are close to making. By identifying and funding promising academic research, and making advances that attract necessary biotechnology support, LLS is rushing to patients the therapies they critically need.

An essential component underlying this research is supporting patients directly. LLS provides up-to-date disease, treatment and survivorship information as well as over $120 million awarded in co-pay assistance for medications and insurance premiums since inception.

As this report goes to press, The Leukemia & Lymphoma Society will have launched a large-scale national media campaign. This important awareness and fundraising effort will differentiate LLS from all charitable causes and focus on the fundamentals of our achievements: We make cures happen. We save lives. We improve quality of life. We give people access to better treatments.

We are one part in the reality business, one part in the business of hope. Our mission is to bring these halves together.

Scott Carroll Someday is today. Chair

3 lls research today

4 My story is a wonderful example of how LLS has changed the world. I was one of the first people in the world, not just the country, to take coming soon: Gleevec®. With Gleevec a world without blood cancers as standard treatment, all I have to do is swallow LLS is committed to life. Our mission is to find cures that make blood cancers a story from six small yellow pills every day to live a normal the past. life with my family and We are making this new world come into being with speed and purpose. friends. Now instead of blood transfusions, During the last 60+ years LLS has invested more than $875 million dollars to develop better staggering fatigue, cancer treatments. persistent nausea and infections, I can walk We have funded the development of nearly every drug that’s been used in the battle against marathons. It’s truly blood cancers. Nearly half of all cancer drugs first approved by the Food and Drug a miracle. I’ve been Administration (FDA) since 2000 were developed for blood cancer patients. taking this breakthrough Since the early 1960s the survival rate for many with leukemia, lymphoma, myeloma and drug for almost 14 years. related blood malignancies has doubled, tripled, even quadrupled. Virginia Garner San Gabriel Valley, CA In 1964 the chance of surviving ALL, the most common childhood leukemia, was 3%. Today it’s 90%. Thanks to LLS support, hundreds of thousands of blood cancer patients today live normal lives. Some manage their condition with just a daily pill, rather than suffer acute treatment such as chemotherapy or radiation as in years past.

Thanks to LLS support, hundreds of thousands of blood cancer patients today live normal lives.

5 a more selective approach to killing cancer cells

They’re called targeted therapies, and they are some of today’s most exciting cancer treatment advances. Like a sharpshooter, Joshua was diagnosed these ingenious drugs take deadly aim at specific abnormal molecules in cancer cells, with leukemia in April and destroy them. 2008. He was at death’s ® ® door by the time we LLS funds have helped advance successful targeted drugs such as Gleevec, Velcade and ® discovered what Dacogen. LLS is currently funding hundreds of researchers who are testing targeted drugs was wrong. It was in new combinations and developing new targeted therapies. Sometimes more than one drug a nightmare no parent is needed to target the same molecular abnormality. LLS helped advance the related drugs, wants to face. Joshua Sprycel® and Tasigna®, for leukemia patients for whom Gleevec wasn’t good enough. began a 3-1/2-year battle ® that he won. We are A new targeted drug Kyprolis — also known as carfilzomib — was recently approved for happy to report that with myeloma patients. It takes aim at the proteasome, a molecular complex that normally degrades the amazing staff at damaged proteins that can otherwise gunk up critical cellular functions. Brenner’s Hospital and Reports show that carfilzomib generally causes fewer neurological side effects than Velcade, many prayers, Joshua is now in remission. the first approved proteasome-inhibiting drug, and can be used safely with other drugs. Last week he scored two Kyprolis is an important new anti-myeloma missile that is also showing activity against other goals in his soccer game cancers, including other blood cancers. that enabled his team to win. We look at this picture now and realize that, at the time, we just wanted him to live. Today he is alive and scoring in his soccer game! Joshua Lancaster West Palm Beach, FL

6 Isaac, an energetic six-year-old, was diagnosed with using your own immune system lymphoma on New Year’s Day 2009. He endured to defeat cancer seven grueling rounds of chemotherapy over Immunotherapies that can selectively enhance anti-cancer immune responses are another 12 weeks, which shrunk exciting area of progress in targeted therapies. the tumor sufficiently so that Isaac underwent Funded by LLS, Dr. Ralph Steinman first began studying an unknown type of immune cell surgery to remove what in 1973. He showed that these so-called dendritic cells can activate other immune cells was left of the tumor. called T cells to promote the immune responses that clear infection from our bodies. Three years later he now Dr. Steinman’s work has led to treatments that stimulate anti-cancer immune responses. enjoys a variety of sports He was awarded the 2011 Nobel Prize in Medicine. and has been on the honor roll for the last At the University of Pennsylvania, Dr. Carl June and his LLS-funded team collected patients’ two years. His family normal T cells and genetically engineered them to display an artificial protein that physically is thankful to LLS and delivers the immune T cells to cancer sites, while other parts of the engineered protein help the researchers who produce additional T cells to amplify the anti-cancer attack. discovered the drugs to treat his lymphoma. People are alive today because of this major contribution. Isaac Bailey Duck In addition to cell-based therapies, LLS-supported researchers have helped to advance Manassas, VA antibody drugs, and anti-cancer vaccines that are already helping patients. Rituxan was the first antibody drug approved as a cancer therapy by the FDA. Rituxan is now widely used in therapies for patients with various forms of lymphoma or chronic lymphocytic leukemia (CLL), and a variety of other malignant and non-malignant diseases. More antibodies are on the way!

Nearly half of all cancer drugs first approved by the FDA since 2000 were developed for blood cancer patients.

7 Kimie enjoys playing with her big brother venture philanthropy: Reese, riding her quad, swimming, and going an investment in saving lives to see Shamu. She has been on radio and TV LLS has a unique infrastructure for identifying and accelerating innovative research for patients and in the newspapers. with unmet medical needs. She is in the 2012 Childhood Cancer For example, LLS proactively supports research focused on reducing the long-term and late Foundations (CCF) effects of today’s blood cancer therapies, so patients who are cured do not face treatment- calendar. Awareness related health concerns later. LLS is funding Dr. Steven Mittelman of Children’s Hospital, and advocacy to continue Los Angeles, to test a vitamin treatment that may prevent some of these complications. blood cancer research has become a major In another focus area, Dr. A. Keith Stewart of the Scottsdale Mayo Clinic is developing new part of her life. Kimie has targeted therapies for patients with myeloma cases that are unlikely to respond to available a rare sub-type of ALL anti-myeloma drugs. called AF4/MLL. She falls outside the known Through TAP, LLS forges partnerships with universities and biotechnology companies, bringing treatment parameters, resources that can more rapidly transform promising research into critically needed therapies, so there isn’t a set including therapies that might otherwise go undeveloped. Through TAP, and further leveraging treatment protocol. She his original focused grant funding, LLS helped Dr. Stewart identify new compounds that inhibit will be followed closely a molecular target called GRK6 that he validated in myeloma. for 10 years. We pray and hope for the best. Also, through TAP, LLS recently gave critical support to Onconova’s rigosertib, a compound under development for patients with high-risk myelodysplastic syndrome (MDS). Baxter Kimie Kiyomi Metcalf International has licensed the European commercial rights for rigosertib, providing significant Chino, CA resources to further advance this drug to patients. As a result of LLS’s long-time grant support (totalling over $20 million) to Dr. Carl June, the University of Pennsylvania and Novartis recently formed an alliance to further develop Dr. June’s groundbreaking immunotherapy approach using engineered T cells to kill cancers. LLS has funded Dr. June and his team for over 20 years to reach this point, enabling their laboratory discoveries to be developed into powerful new treatments and ultimately attracting a partner of the caliber of Novartis. These focused funding mechanisms and collaborations, which raise promising therapies to the next level of funding, are a persuasive reason to believe that someday is today.

8 I got the diagnosis of stage 4 follicular, how to turn old drugs into new center cell, non-Hodgkin lymphoma. I started life-saving therapies treatment as quickly as possible, and soon In the past, finding new uses for old drugs was largely fortuitous. Today, scientists are using learned to live with special technologies to match already approved drugs to new purposes. This sharply reduces being bald and tired. the time and cost of getting therapies to patients who need them. The doctors, physician’s assistants and nurses Last year LLS entered into a unique public/private collaboration called the Learning were awesome, but Collaborative with the University of Kansas Cancer Center and the National Institutes of Health the real heroes were (NIH) to repurpose existing drugs to treat blood cancer patients. The first project is a clinical my family and friends. trial of auranofin, a rheumatoid arthritis therapy, as a treatment for patients with chronic Lisa and the kids were lymphocytic leukemia. Auranofin has moved from rediscovery to clinical testing in an unusually incredible. My mom and short time. dad stayed three days a week. Neighbors and LLS has also partnered with Princess Margaret Hospital in Toronto, University of Kansas, friends organized dinner and a private company to advance an antifungal agent as a potential treatment for patients deliveries that spoiled with acute myeloid leukemia (AML). Laboratory tests showed that the agent, called CPX, us beyond belief. They can be effective against leukemia cells as well as fungal infections. Now the drug is being did whatever driving tested in a clinical trial in blood cancer patients, including AML patients. we needed. Eight months later, a clean bill of health Other examples include drugs approved to treat viral infections and diabetes that are showing and a 170-person real promise as new treatments for blood cancer patients. For over 60 years recovery party put this LLS has invested one in the books. more than Arthur Valentine $875 million in Narberth, PA developing better cancer treatments.

9 lls advocacy today

10 fighting for the right to fair patient treatment

We took our 22-month- old daughter to the Since our founding in 1949, LLS has fought for better public policy on essential patient needs pediatrician in through advocacy. This year LLS brought more than 150 volunteers and staff to Capitol Hill November 2011. She to push for passage of the Prescription Drug User Fee Act (PDUFA); funding for a new institute was experiencing high at NIH called the National Center for Advancing Translational Sciences/Cures Acceleration fevers and was having trouble walking. After Network (NCATS/CAN); and for oral-IV (intravenous) parity legislation. many long hours and PDUFA was signed into law with impressive bipartisan support, demonstrating that cancer lots of tests, it was takes no political side when patients express their collective will loud and clear. The law confirmed that Maddy both accelerates the development of new treatments and cures and brings additional focus had ALL. After a grueling to the issue of drug shortages, which is of critical importance to LLS and our patients. nine months of intensive NCATS/CAN is providing grants and contracts to academic researchers, pharmaceutical treatment, Maddy is now and biotechnology companies, and private research foundations to facilitate work on “high in long-term maintenance need” treatments. Collaborating with the University of Kansas Cancer Center and NCATS, and is doing amazingly LLS created the “Learning Collaborative” to serve as a model for expediting new treatments well. We are so thankful for rare or neglected diseases. for our doctors, nurses, friends and family who giving patients access to what their doctor recommends have stood by our side and supported us during LLS believes every cancer patient should be able to take advantage of the treatment this crisis. And we are regimens recommended by their physician. This year, LLS-led coalitions in multiple states so incredibly grateful for resulted in the passage of oral-IV parity bills that improve access to oral and other patient the advances in treatment self-administered drugs. These drugs are more widely used in blood cancer treatments that are making it possible but are prohibitive due to high cost-sharing and co-pay requirements. The oral-IV parity bills for our precious daughter are intended to ensure patients’ coverage at a cost equal to what they would have paid to survive and thrive. for an IV or other physician-administered drug. Erin McCarthy These bills have now been passed in 20 states plus the District of Columbia. LLS is now Chicago, IL also leading a study of the effects that these new laws have had on patient access.

helping to make the FDA more effective

LLS coordinates with our field advocates to drive better public policy for patients. And by working through the FDA we promote the development and approval of new blood cancer treatments. We also work to ensure that patients can access these new treatments by pressing for reimbursement policies to cover high quality cancer care. Our TAP program sets a high standard, but we have further to go. To truly achieve the promise of personalized medicine, LLS must bring to bear resources that reflect our role as a leader in research, patient services and support, as well as developing Join us today public policies that ensure treatments and services are accessible to every patient by emailing who needs them. [email protected].

11 lls patient services today

12 continuing support for patients, family members and caregivers

Today no blood cancer patient will have to worry about having up-to-date information and support. This is readily available for all blood cancer patients through LLS programs and services. Two years ago LLS began a groundbreaking series to educate oncologists and primary care physicians about sharing care for blood cancer survivors. In 2012 the LLS program Ongoing Nursing Management of Cancer Survivors: I am now an eight-year Collaboration Between Oncology and Primary Care discussed side effects management survivor and have and other quality of life issues. surpassed my original hope of seeing my son doctors’ choice for the most helpful co-pay foundation graduate from college In 2011 oncologists rated the LLS Co-Pay Assistance Program first in the nation in terms of and my daughter finish helping their patients. The program provides support for prescription drug co-pays and health high school. I will always be in treatment because insurance premiums for blood cancer patients who meet diagnosis and income requirements. there is no cure for CML. LLS has awarded over $120 million to eligible patients since this program’s inception. I am grateful to LLS for their relentless efforts to giving patients access to in-depth individual attention find a cure and for Through the Information Resource Center (IRC), specialists help patients connect with clinical supporting the research trials and with LLS national education programs. These specialists also work with LLS to develop the tyrosine community-based patient services managers, providing information about local healthcare kinase inhibitor drugs resources and chapter education and support. that keep me alive. I try to give back by advances in blood cancer: webcasts and other new resources raising funds through TNT. I have completed To help patients feel more prepared to discuss treatment with their doctor, LLS launched 21 TNT athletic events a series of webcasts to inform them about the latest advances in blood cancer treatment. and am a TNT Triple Update on Treatment for NHL and CLL, a webcast in the Advances in Blood Cancer Series, Crown Athlete. Today leads patients toward getting an accurate diagnosis. I work as a Cancer New 2012 programs and services also include the chronic myeloid leukemia (CML) blog, Care Coordinator and a discussion of key issues for CML survivors; and the CML Tracker, a mobile tool to keep track help newly diagnosed cancer patients navigate of appointments, medications and test results. LLS’s innovative the health care system. programs and lls education programs and support services Every day is a miracle. services are reviewed by LLS chapter, national staff and volunteers provide programs and services that encompass Gail Stephens nationally Orange, CA total patient care. Chapter staff maintain relationships with local medical and advocacy recognized organizations. They close cultural gaps for under-represented cancer patient populations. thought leaders Through a peer support program, the Patti Robinson Kaufmann First Connection Program, in hematology LLS-trained volunteers meet the needs of the blood cancer community. and oncology.

13 lls fundraising today

14 targeted giving and bequests that help bring someday to today

Someday could not be today without the help of thousands of donors who choose to forgo the range of LLS athletic and community fundraising activities in favor of a direct giving option. Using checks, appreciated stock or by clicking online, they experience the satisfaction of giving and making an impact through donations large and small. Some give in honor of another’s success or in memory of someone lost. Others, making charitable investments of $10,000 or more, focus their giving on a particular type of blood cancer by choosing among a dozen disease-specific research portfolios. This year we have had two significant commitments totaling $3.5 million from The Edward At the age of two I was P. Evans Foundation and the Harry T. Mangurian, Jr. Foundation. Both are supporting an diagnosed with ALL. advanced phase clinical trial of a new treatment for patients with myelodysplastic syndromes Since my treatment to prevent the disease from advancing to an especially dangerous form of acute leukemia. my family has been very involved in different Still others, apart from their lifetime charitable giving, make bequest commitments either fundraising events. I was through a will or as a beneficiary in a retirement plan. By naming a specific amount or a fraction a patient hero for Team of an estate or retirement account, donors keep assets for as long as needed. Afterwards, In Training. I did several the stipulated amount supports life-saving research or services for patients. Light The Night Walks. I used to get mad because This year LLS received more than $5 million from bequests of all sizes, and we welcomed many I had to carry a white new members to our Legacy Circle, the valued group of friends who have let us know about balloon and everyone their future intentions through their estate plans. else had a red one. I wanted to carry the red ones. I didn’t understand until later that having the school & youth programs white balloon made me schoolandyouth.org special. I was declared cancer-free at age five and I’ve been cancer-free This year School & Youth Programs® — Pennies for Patients® and Olive Garden’s Pasta for ever since. I won the Pennies® — generated a record-breaking $29.1 million. And Olive Garden’s Pasta for Pennies battle. I beat cancer, but hit a milestone, raising over $70 million since its inception. I had many friends in the School & Youth Programs show students how their involvement can have life-saving impact hospital and the doctors’ Someday could on blood cancer patients. Students collect spare change over a three-week period during office that lost the battle. not be today I will miss them. February or March. The change can come from friends, relatives or under couch cushions. without the help Victoria Callihan The programs are an important learning tool for kids. Over 27,000 schools registered to of thousands McLean, VA participate in the 2012-13 School & Youth Programs. a 7% increase over 2011. And the of donors using fundraising average for participating schools increased by 4%, due largely to an increase a direct giving of LLS staff visiting schools for program kick-off assemblies and program planning meetings. option that better suits their lifestyle.

15 In April 2008 I was diagnosed with CLL. The type of leukemia I have has no cure. Yet. So I am in “active man & woman of the year treatment.” Six months mwoy.org after finishing chemo, I found TNT. I credit TNT with helping to keep me This spirited fundraising competition is held in communities across the U.S. Participants healthier and more sane compete for the title of Man or Woman of the Year. Each candidate relies on family, friends for the last four years. and business contacts to raise as much money as possible. They raise funds for blood cancer My “numbers” have research in honor of local children who, as Boy and Girl of the Year, are blood cancer survivors. been slowly growing and I am now to a point In 2012 there were 71 campaigns in North America. Over 800 honored candidates collectively where I will be needing raised a record-breaking $19.2 million. chemo again. If it keeps me here four years The National Man of the Year was Tommy Cleaver of CBRE (Team Name “Living Proof”) or more, I’ll do it, no and the National Woman of the Year was Mary Pillsbury Wainwright of Mary Pillsbury Fine problem. I have been Jewelry Co. Together, they raised a total of over $530,000. blessed to have been able to do 18 endurance events. Karin O’Brien team in training Portland, OR teamintraining.org

Once again Team In Training® (TNT) is this year’s industry leader in charity endurance sports training programs raising over $81 million in fiscal year 2012. 2,300 experienced coaches across North America delivered “champion-level” training to 40,000 participants, preparing them to succeed in the event they chose. Not surprisingly, the TNT Corporate Team Development program grew 40% year-over-year, driven by 57 new and returning national teams, and presented 15 Recognition Awards to high fundraising teams who surpassed $100K.

16 leukemia cup regatta leukemiacup.org

Held at yacht clubs and other locations across North America, the Leukemia Cup Regatta® is a thrilling series of sailing events that combines the excitement of boating with the important contribution of raising money to cure cancer. Since its inception, the Leukemia Cup Regatta has raised over $42 million. Skippers register their boats and recruit friends and colleagues to help crew and to raise I had stage 4 non- funds. With national and local event sponsors also supporting Regatta, 2012 was a record- Hodgkin lymphoma. setting year with nearly $4.4 million raised at 50 events. Over 100 top fundraisers participated I’ve gotten chemo, radiation and a stem in the Fantasy Sail with Gary Jobson in New York Harbor in October 2011. cell transplant. The The October 2011 San Francisco Yacht Club Leukemia Cup was the first LLS Regatta venue transplant was by far to raise $1 million; while the Annapolis sailing community marked the 20th anniversary of their the hardest part. I’ve Leukemia Cup Regatta. been in remission since 2009. I got involved with LLS in 2009. Nonetheless I feel lucky to have not only survived but to have light the night walk gotten sick to begin lightthenight.org with. I think many cancer survivors feel that way. Our annual Light The Night® Walk continues to engage the business community, patients Nearly losing your life and their families. Walking in nearly 200 communities across the U.S. and Canada, 250,000 quickly teaches you how supporters walk to raise funds in honor of survivors, in memory or in support of anyone valuable it really all is, touched by blood cancer. and it’s easy for people to overlook that on Since inception, we have raised over $400 million, but last year, walks raised an historic a day-to-day basis. recordbreaking total of over $50 million. Our much honored friend, Burlington Coat Factory, Still, I don’t wish the raised over $2.9 million last year alone, bringing their total amount to $12 million in the past experience on anyone 10 years. And the ongoing development of local volunteer leadership, including Corporate else and that’s why Walk Chairs and Executive Committees, continues to pave the way to increased revenue Once again Team I fundraise. for LLS. In Training (TNT) James DeMasi is this year’s Philadelphia, PA industry leader in charity endurance sports training programs.

17 research grants

Larry Kwak, MD, PhD Meztli Arguello, PhD Dinis Calado, PhD Chen Dong, PhD Andrei Goga, MD, PhD* The Marshall A. Lichtman University of Texas University of Montreal Max Delbruck Center University of Texas University of California, Specialized Center M.D. Anderson Cancer Center for Molecular Medicine (MDC) M.D. Anderson Cancer Center San Francisco of Research Scott Armstrong, MD, PhD 8 Jonathan Licht, MD 4* Children’s Hospital Boston George Calin, MD Yali Dou, PhD* Ananda Goldrath, PhD The Specialized Center of Northwestern University University of Texas University of Michigan University of California, San Diego Laura Attardi, PhD Research Program funds School of Medicine M.D. Anderson Cancer Center Stanford University Mary Eapen, MD 12 Ajay Gopal, MD multi-disciplinary research by Scott Lowe, PhD 5 Asher Chanan-Khan, MD Medical College of Wisconsin University of Washington teams of leading-edge academic Lukas Baitsch, PhD* Sloan-Kettering Institute Mayo Clinic and Foundation, investigators that hasten the Dana-Farber Cancer Institute Benjamin Ebert, MD, PhD* Daniel Gough, PhD for Cancer Research Jacksonville discovery and development Brigham & Women’s Hospital Monash University Cynthia Barber, PhD of better treatments for leukemia, Beverly Mitchell, MD 6 Iain Cheeseman, PhD* Brandeis University Anna Eiring, PhD Michael Green, PhD* lymphoma and myeloma patients. Stanford University Whitehead Institute University of Utah Stanford University A center is composed of at least Craig Bassing, PhD for Biomedical Research three independent research The Children’s Hospital Chong Chen, PhD Suhua Feng, PhD Yoon-Chi Han, PhD programs that are integrated of Philadelphia Memorial Sloan-Kettering University of California, Memorial Sloan-Kettering and supported by scientific Career Development Cancer Center Los Angeles Cancer Center core laboratories. Cristian Bellodi, PhD Program 7 University of California, Jing Chen, PhD David Ferguson, MD, PhD Omid Harandi, PhD San Francisco University of Michigan University of Massachusetts Jerry Adams, PhD * Emory University The Career Development Program Medical School Walter & Eliza Hall Institute Anja-Katrin Bielinsky, PhD * Maria Figueroa, MD provides stipends to investigators Mo Chen, PhD of Medical Research University of Minnesota, Rockefeller University Weill Medical College Jorge Henao-Mejia, MD, PhD of exceptional promise in the early Twin Cities of Cornell University Yale University Frederick Alt, PhD stages of their careers, helping Tao Cheng, MD * Immune Disease Institute them devote their careers to Michael Boddy, PhD University of Pittsburgh Elsa Flores, PhD Daniel Herranz, PhD The Scripps Research Institute University of Texas Columbia University * research in leukemia, lymphoma Jon Aster, MD Uhn-Soo Cho, PhD M.D. Anderson Cancer Center Medical Center or myeloma. 9 Brigham & Women’s Hospital Marina Bousquet, PhD University of Michigan INSERM – Cancer Research Jonathan Friedberg, MD Erin Hertlein, PhD 1 John Byrd, MD Gregory Abel, MD* Center of Toulouse Yuh Min Chook, PhD University of Rochester The Ohio State University The Ohio State University Dana-Farber Cancer Institute University of Texas Troy Brady, PhD Maxim Frolov, PhD Jonathan Higgins, PhD 2 Southwestern Medical Center Riccardo Dalla-Favera, MD Cassandra Adams, PhD* University of Pennsylvania University of Illinois, Chicago Brigham & Women’s Hospital Columbia University University of California, Christopher Cogle, MD* Sarah Brennan, PhD*/ Karen Gascoigne, PhD* Andrew Holland, PhD 3 San Francisco University of Florida Brian Druker, MD Cihangir Duy, PhD 10 Whitehead Institute Ludwig Institute Oregon Health & Science Tahamtan Ahmadi, MD, PhD Weill Medical College Hauke Cornils, PhD* for Biomedical Research for Cancer Research University University of Pennsylvania of Cornell University Dana Farber Cancer Institute Ulrike Gerdemann, MD Kuo-Chiang Hsia, PhD* Anthony Green, MD, PhD Colin Aitken, PhD Jennifer Brown, MD, PhD Naomi Courtemanche, PhD Baylor College of Medicine Rockefeller University University of Cambridge Johns Hopkins University Dana-Farber Cancer Institute Yale University Yun Huang, PhD School of Medicine Nilanjan Ghosh, PhD Helen Heslop, MD Patrick Brown, MD 11 Matthew Davids, MD Johns Hopkins University La Jolla Institute for Allergy Baylor College of Medicine Arash Alizadeh, MD, PhD Johns Hopkins University Dana-Farber Cancer Institute School of Medicine and Immunology Stanford University School of Medicine Carl June, MD Michael Deininger, MD, PhD Evisa Gjini, PhD Enfu Hui, PhD University of Pennsylvania K Mark Ansel, PhD* Claudio Brunstein, MD, PhD University of Utah Dana-Farber Cancer Institute University of California, University of California, San Francisco University of Minnesota, David DiLillo, PhD* San Francisco Twin Cities Rockefeller University

1 Dr. John Byrd is funded in part 2 Dr. Riccardo Dalla-Favera is funded 3 Dr. Brian Druker is funded in part 5 Dr. Scott Lowe is funded in part 6 Dr. Beverly Mitchell is funded 7 LLS Career Development Program by Gerald Kafka and Rita Cavanagh, in part by The Paul E. Singer Family by the F.M. Kirby Foundation, Inc. by the Altschul Foundation – in part by The Joseph C. Sanfilippo is funded in part by the Leo W. the Jim Jacobs Charitable Reichman Memorial, and the Memorial Fund, an advised fund of and Lilyan E. Cole Fund. Foundation, Joseph S. and Diane H. 4 Dr. Jonathan Licht is funded in part Foundation, Stanley and Sandra Amanda Wins Fund. Saratoga Monte Sereno Community Steinberg Charitable Trust and the by The Pamela B. Katten Memorial 8 Dr. Scott Armstrong is funded in part Kahan, Douglas A. and Phyllis Smith, Foundation, and The Harry T. J.T. Tai & Co. Foundation, Inc. Leukemia Research Foundation. by The For Julie Foundation, Inc. Elaine Smith and Michael and Judy Mangurian, Jr. Foundation, Inc. and an anonymous donor. Thomas.

18 Jared Johnson, PhD* Mark Levis, MD, PhD 13 James Mulloy, PhD Jae Park, MD 16 Julien Sage, PhD Jamie Spangler, PhD* Beth Israel Deaconess Johns Hopkins University Cincinnati Children’s Hospital Memorial Sloan-Kettering Stanford University Stanford University Medical Center School of Medicine Medical Center Cancer Center Sandrine Sander, MD, PhD Till Strowig, PhD Brian Jonas, MD, PhD* Yan Li, PhD* Jagan Muppidi, MD, PhD* Emmanuelle Passegué, PhD* Max Delbruck Center Yale University Stanford University University of Pennsylvania University of California, University of California, for Molecular Medicine (MDC) Jason Stumpff, PhD San Francisco San Francisco Tarun Kapoor, PhD Zejuan Li, PhD Karsten Sauer, PhD University of Vermont Rockefeller University The University of Chicago Markus Muschen, MD Danilo Perrotti, MD, PhD 17 The Scripps Research Institute Mayumi Sugita, MD* University of California, The Ohio State University * Aaron Schimmer, MD, PhD Barbara Kee, PhD Kaifeng Lin, PhD San Francisco University of Pennsylvania The University of Chicago University of North Carolina Cathie Pfleger, PhD* University Health Network Kelly Sullivan, PhD at Chapel Hill Shalin Naik, PhD Mount Sinai School of Medicine Baerbel Schroefelbauer, PhD Hyungjin Kim, PhD The Netherlands Cancer Institute University Of Colorado Dana-Farber Cancer Institute Kevin Lin, PhD Daniel Pollyea, MD 18 University of California, San Diego Wojciech Swat, PhD British Columbia Cancer Agency Geeta Narlikar, PhD University of Colorado Rosalie Sears, PhD Mi-Yeon Kim, PhD University of California, Washington University in St. Louis Columbia University Camille Lobry, PhD* Joel Pomerantz, PhD Oregon Health & Science San Francisco David Sykes, MD, PhD Medical Center New York University Johns Hopkins University University Massachusetts General Hospital School of Medicine Kristi Norris, PhD School of Medicine Julianne Kitevski-LeBlanc, PhD Neil Shah, MD, PhD Duke University Medical Center Yvonne Tay, PhD University of Toronto Alexis Lomakin, PhD* Alexandre Puissant, PhD* University of California, Beth Israel Deaconess Harvard Medical School Voytek Okreglak, PhD Dana-Farber Cancer Institute San Francisco Myung Ko, PhD University of California, Medical Center La Jolla Institute for Allergy Sonja Lorenz, PhD 19 Tait Shanafelt, MD* San Francisco Noopur Raje, MD Benjamin Thompson, PhD* and Immunology University of California, Berkeley Massachusetts General Hospital Mayo Clinic and Foundation Virginie Olive, PhD* Northwestern University Robert Signer, PhD Andrew Koh, PhD Sami Malek, MD University of California, Berkeley Jeffrey Rathmell, PhD Chicago Campus Stanford University University of Michigan Duke University Medical Center University of Texas Southwestern Kyla Omilusik, PhD* Medical Center Sarah Thompson, MD, PhD Holbrook Kohrt, MD 14 William Matsui, MD University of California, San Diego Pavan Reddy, MD University of Manchester Stanford University Johns Hopkins University Lev Silberstein, MD, PhD* University of Michigan Joanna Tober, PhD School of Medicine Tonis Org, PhD* Massachusetts General Hospital Marina Konopleva, MD, PhD University of California, Boris Reizis, PhD University of Pennsylvania University of Texas Alexander Mazin, PhD Jeffrey Skaar, PhD Los Angeles Columbia University David Traver, PhD* M.D. Anderson Cancer Center Drexel University Medical Center New York University Elisa Oricchio, PhD* School of Medicine University of California, San Diego Rhett Kovall, PhD Megan McNerney, MD, PhD Memorial Sloan-Kettering Ran Reshef, MD * University of Cincinnati Jane Skok, PhD Amit Verma, MD The University of Chicago Cancer Center University of Pennsylvania New York University Albert Einstein College of Medicine Maxwell Krem, MD, PhD 15 Hanna Mikkola, MD, PhD Christopher Ott, PhD* Giovanni Roti, MD, PhD School of Medicine of Yeshiva University Fred Hutchinson Cancer University of California, Dana-Farber Cancer Institute Dana-Farber Cancer Institute Roumen Voutev, PhD Research Center Los Angeles Catherine Smith, MD Kostandin Pajcini, PhD James Rubenstein, MD, PhD University of California, Columbia University Andrew Lane, MD, PhD* Sarah Mitchell, PhD* University of Pennsylvania University of California, San Francisco Medical Center Dana-Farber Cancer Institute University of Colorado San Francisco * Qishen Pang, PhD Merav Socolovsky, MD, PhD* Youzhong Wan, PhD Anthony Letai, MD, PhD Stefanie Mortimer, PhD Cincinnati Children’s Hospital Loredana Ruggeri, MD, PhD University of Massachusetts Dana-Farber Cancer Institute Dana-Farber Cancer Institute University of California, Berkeley Medical Center University of Perugia Medical School Hengbin Wang, PhD * Ross Levine, MD Britta Mueller, PhD Davide Ruggero, PhD Richelle Sopko, PhD* The University of Alabama Memorial Sloan-Kettering Massachusetts General Hospital University of California, Harvard Medical School at Birmingham Cancer Center San Francisco

9 Dr. Marina Bousquet is fully funded 11 Dr. Patrick Brown is fully funded 14 Dr. William Matsui is the Millennium: 16 Dr. Jae Park is funded in part 18 Dr. Daniel Pollyea is the Sally P. * Newly awarded or renewed grants by the Gertrude B. Elion Endowment by The Orokawa Foundation. The Takeda Oncology Company by Scot Stevens. Turpin Clinical Researcher. in fiscal year 2013 Fund. Scholar. 12 Dr. Mary Eapen is funded in part 17 Dr. Danilo Perrotti is funded in part 19 Dr. Noopur Raje is the Millennium: 10 Dr. Cihangir Duy is funded by by Hertha Malz. 15 Dr. Hanna Mikkola is funded in part by Charles and Lynda Kraemer The Takeda Oncology Company the Jake Wetchler Fellowship for by Parents Against Leukemia. and Mark and Christine Kraemer. Scholar. 13 Dr. Mark Levis is the Rally Foundation Pediatric Innovation. for Childhood Cancer Research Scholar. 19 research grants (continued)

Lin Wang, PhD* Lee Zou, PhD Steven Bernstein, MD Jayne Danska, PhD Monica Guzman, PhD Jennifer Levine, MD* University of California, Berkeley Massachusetts General Hospital University of Rochester The Hospital for Sick Children Weill Medical College Columbia University of Cornell University Matthew Warr, PhD* Elina Zuniga, PhD* Smita Bhatia, MD, MPH* Eduardo Davila, PhD Ross Levine, MD University of California, University of California, San Diego Beckman Research Institute University of Maryland Duane Hassane, PhD* Memorial Sloan-Kettering San Francisco of the City of Hope Weill Medical College Cancer Center James DeGregori, PhD of Cornell University Rei Watanabe, MD, PhD Bruce Blazar, MD* University of Colorado Ronald Levy, MD Brigham & Women’s Hospital University of Minnesota, Christoph Heuck, MD Stanford University Translational Research Michael Deininger, MD, PhD Twin Cities University of Arkansas Jeremy Wilusz, PhD Program University of Utah * for Medical Sciences Mignon Loh, MD Massachusetts Institute Katherine Borden, PhD University of California, Nicholas Donato, PhD of Technology University of Montreal Ronald Hoffman, MD* San Francisco The Translational Research University of Michigan Mount Sinai School of Medicine Jennifer Woodard, PhD Program supports outstanding Vassiliki Boussiotis, MD, PhD A. Look, MD Alan Eastman, PhD The University of Chicago investigations deemed by our Beth Israel Deaconess Robert Hromas, MD* Dana-Farber Cancer Institute Dartmouth College expert advisors most likely Medical Center University of Florida Jennifer Woyach, MD to translate basic biomedical Leo Luznik, MD* Adolfo Ferrando, MD, PhD The Ohio State University discoveries into new, safe Jennifer Brown, MD, PhD* Xianxin Hua, MD, PhD Johns Hopkins University Columbia University and effective treatments, Dana-Farber Cancer Institute University of Pennsylvania School of Medicine Mingyi Xie, PhD* ultimately prolonging and Varsha Gandhi, PhD Yale University Patrick Brown, MD Richard Jones, MD* Jaroslaw Maciejewski, MD, PhD* enhancing patients’ lives. University of Texas Johns Hopkins University Johns Hopkins University Cleveland Clinic Foundation Wen Xue, PhD M.D. Anderson Cancer Center School of Medicine School of Medicine Massachusetts Institute Ravindra Majeti, MD, PhD Iannis Aifantis, PhD Irene Ghobrial, MD* of Technology John Byrd, MD Craig Jordan, PhD 23 Stanford University New York University Dana-Farber Cancer Institute The Ohio State University University of Rochester Rushdia Yusuf, MD School of Medicine Tak Mak, PhD* Steven Grant, MD 22 * Massachusetts General Hospital Jose Cancelas, MD, PhD* Carl June, MD 24 University Health Network Shabbir Alibhai, MD Virginia Commonwealth University Cincinnati Children’s Hospital University of Pennsylvania Chongzhi Zang, PhD* University Health Network Sami Malek, MD* Medical Center Steven Gore, MD Dana-Farber Cancer Institute Kala Kamdar, MD University of Michigan Raquel Aloyz, PhD Johns Hopkins University Jennifer Carew, PhD* Baylor College of Medicine Karl Zawadzki, PhD Lady Davis Institute University of Texas Health School of Medicine Ari Melnick, MD Stanford University for Medical Research Scott Kaufmann, MD, PhD* Weill Medical College Science Center at San Antonio Timothy Graubert, MD* Mayo Clinic and Foundation of Cornell University Ji Zhang, PhD Stephen Ansell, MD, PhD* Washington University in St. Louis Selina Chen-Kiang, PhD 20 Sloan-Kettering Institute Mayo Clinic and Foundation John Koreth, MD, PhD Rodney Miles, MD, PhD* Weill Medical College Jolanta Grembecka, PhD for Cancer Research Dana-Farber Cancer Institute University of Utah Saro Armenian, DO, MPH of Cornell University University of Michigan Zhiguo Zhang, PhD Beckman Research Institute Donald Kufe, MD Beverly Mitchell, MD Eric Chow, MD* James Griffin, MD* Mayo Clinic and Foundation of the City of Hope Dana-Farber Cancer Institute Stanford University Fred Hutchinson Dana-Farber Cancer Institute Grace Zheng, PhD* Maria Baer, MD Cancer Research Cente John Kuruvilla, MD* Steven Mittelman, MD, PhD 26 H. Leighton Grimes, PhD* Stanford University University of Maryland University Health Network Children’s Hospital Los Angeles John Crispino, PhD 21 * Cincinnati Children’s Hospital Leif Bergsagel, MD* Bo Zhou, PhD* Northwestern University Medical Center Larry Kwak, MD, PhD 25 Jeffrey Molldrem, MD Mayo Clinic and Foundation University of Texas Southwestern University of Texas University of Texas Alan D’Andrea, MD* Monica Guzman, PhD Medical Center M.D. Anderson Cancer Center M.D. Anderson Cancer Center Irwin Bernstein, MD* Dana-Farber Cancer Institute Weill Medical College Yubin Zhou, PhD Fred Hutchinson of Cornell University * Markus Muschen, MD Chi Dang, MD, PhD Anthony Letai, MD, PhD La Jolla Institute for Allergy Cancer Research Center University of California, University of Pennsylvania Dana-Farber Cancer Institute and Immunology San Francisco

20 Dr. Selina Chen-Kiang is funded in 22 Dr. Steven Grant is funded in part 23 Dr. Craig Jordan is funded in part 25 Dr. Larry Kwak is funded part by Alexandra Mayes Birnbaum by The Familant Family Research by The For Julie Foundation, Inc. by The Mansbach Foundation, Inc. and the LLS New York City Chapter Fund. 24 Dr. Carl June is the Imagine 26 Board of Trustees. Dr. Steven Mittelman is funded a Cure for Leukemia’s Translational in part by the California Community 21 Dr. John Crispino is funded in part Researcher and is funded in part Foundation. by The Pamela B. Katten Memorial by the Familant Family Research Leukemia Research Foundation. Fund.

20 Steffan Nawrocki, PhD David Scheinberg, MD, PhD Andrea Velardi, MD Shape Pharmaceuticals, Inc. Waldenstroms University of Texas Health Sloan-Kettering Institute University of Perugia Therapy Acceleration Cambridge, MA Macroglobulinemia Science Center at San Antonio for Cancer Research Program Partnerships Amit Verma, MD Projects † Aaron Shimmer, MD, PhD Sattva Neelapu, MD Aaron Schimmer, MD, PhD* Albert Einstein College University Health Network University of Texas University Health Network of Medicine M.D. Anderson Cancer Center Stephen Ansell, MD Acetylon Pharmaceuticals, Inc. Chantal Séguin, MD Shaomeng Wang, PhD Mayo Clinic and Foundation Boston, MA Ruben Niesvizky, MD* McGill University University of Michigan Weill Medical College Asher Chanan-Khan, MD Ascenta Therapeutics, Inc. * of Cornell University Jonathan Serody, MD Y. Lynn Wang, MD, PhD Mayo Clinic and Foundation, Malvern, PA University of North Carolina Weill Medical College Jacksonville Owen O’Connor, MD, PhD* of Cornell University Avila Therapeutics, Inc. * Columbia University Neil Shah, MD, PhD Irene Ghobrial, MD (Celgene Avilomics Research) University of California, Ryan Wilcox, MD, PhD* Dana-Farber Cancer Institute Waltham, MA Tiong Ong, MD San Francisco University of Michigan National University of Singapore Celator Pharmaceuticals, Inc. Neil Shah, MD, PhD Catherine Wu, MD* Princeton, NJ Samir Parekh, MD University of California, Dana-Farber Cancer Institute Myelofibrosis Concept Christopher Cogle, MD Albert Einstein College San Francisco Grants †† of Medicine Feng-chun Yang, MD, PhD University of Florida Rita Shaknovich, MD, PhD Indiana University Angel Pellicer, MD, PhD Weill Medical College Curis, Inc. * New York University of Cornell University Peter Zandstra, PhD Benjamin L. Ebert, MD, PhD Lexington, MA University of Toronto School of Medicine Ann Mullally, MD James DeGregori, PhD Margaret Shipp, MD* Brigham & Women’s Hospital Josef Prchal, MD* Dana-Farber Cancer Institute Fenghuang Zhan, MD, PhD University of Colorado University of Utah University of Utah Pearlie Epling-Burnette, PhD Varda Shoshan-Barmatz, PhD Epizyme, Inc. * Adam Mailloux, PhD Elizabeth Raetz, MD Ben-Gurion University Li Zhang, PhD Cambridge, MA University Health Network H. Lee Moffitt Cancer Center New York University of the Negev Mark Frattini, MD, PhD School of Medicine C. Arnold Spek, PhD Alexander Stewart, MD* Memorial Sloan-Kettering Center for Experimental Cancer Center Anjana Rao, PhD Mayo Clinic and Foundation and Molecular Medicine La Jolla Institute for Allergy Roger Strair, PhD Jolanta Grembecka, PhD and Immunology Amit Verma, MD University of Michigan UMDNJ – Robert Wood Johnson Zhizhuang Joe Zhao, PhD Pavan Reddy, MD* Medical School Albert Einstein College of Medicine Judith Karp, MD University of Michigan Samuel Strober, MD* Johns Hopkins University, Sidney Kimmel Comprehensive Susan Rheingold, MD 27 Stanford University Cancer Center The Children’s Hospital Michael Thirman, MD* of Philadelphia The University of Chicago Ari Melnick, MD Weill Medical College Alain Rook, MD* Raoul Tibes, MD, PhD of Cornell University University of Pennsylvania Mayo Clinic and Foundation Onconova Therapeutics, Inc. Daniela Salvemini, PhD Francisco Vega, MD, PhD Newtown, PA Saint Louis University University of Texas Barbara Savoldo, MD, PhD* M.D. Anderson Cancer Center Baylor College of Medicine

27 Dr. Susan Rheingold is funded * Newly awarded or renewed grants † Partner grants with the International in part by The Critchley Family. in fiscal year 2013 Waldenstroms Macroglobulinemia Foundation (IWMF) †† Partner grants with the Myeloproliferative Neoplasm Research Foundation (MPNRF)

21 research portfolios advisors

LLS Research Portfolios 1 Acute Lymphoblastic Leukemia Research Portfolio is funded in part Catriona Jamieson, MD, PhD are groups of research by Megan’s Wings, Inc. and Deborah Tobias – Translational Research Medical + Scientific University of California, San Diego Therapy Acceleration projects organized around Program. Affairs Committee Alan List, MD Program Committee a specific blood cancer 2 Acute Myeloid Leukemia and Myelodysplastic Syndromes Research H. Lee Moffitt Cancer Center interest. The list below Portfolio is funded in part by Hildegarde D. Becher Foundation, Inc., includes donors that Greg and Michelle Becker, the Dallas Saint Valentine’s Luncheon and Chair Robert Negrin, MD A. Dana Callow, MBA generously invested in Fashion Show, King & Spalding, LLP, Neil Kishter, The Douglas Kroll Armand Keating, MD Stanford University Boston Millennia Partners a specific LLS research Research Foundation, Mike and Kathy Ladra, Peter and Tina Locke, Princess Margaret Hospital Susan M. O’Brien, MD The Robert H. Lyon Leukemia Foundation, Clyde Smith McGregor and Gary C. Cupit, PharmD portfolio during this fiscal University of Texas LeAnn Pedersen Pope – In Memory of Joan Kowing McGregor, The Somnus Therapeutics, Inc. year. M.D. Anderson Cancer Center Morrison-Minton Family Trust, Guy and Linda Nohra, Jeff and Pat Sachs, Frederick Appelbaum, MD James H. Davis, PhD, JD the LLS Silicon Valley & Monterey Bay Area Chapter Board of Trustees, Fred Hutchinson Cancer Derek Raghavan, MD, PhD Human Genome Sciences, Inc. Acute Lymphoblastic Michael and Elizabeth Sweeney, and TCDI. Carolinas HealthCare System 1 Research Center Leukemia 3 Ian W. Flinn, MD, PhD Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Steven Rosen, MD the American Construction Co., Inc., Stephen and Madeline Anbinder, Irwin Bernstein, MD Tennessee Oncology Acute Myeloid Leukemia and Fred Hutchinson Cancer Northwestern University 2 Paul and Helen Anbinder, Bob Cooper CLL Research Fund, Andrew F. Jennifer Gordon, PhD Myelodysplastic Syndromes Research Center Gulli, Cora and John H. Davis Foundation, Thomas and Laurie Saylak, Franklin O. Smith, MD Baker Botts, LLP Chronic Lymphocytic the George L. Shields Foundation and Siuslaw Bank. Steven Bernstein, MD University of Cincinnati Richard L. Jackson, PhD Leukemia 3 4 Chronic Myeloid Leukemia Research Portfolio is funded in part University of Rochester Nancy Speck, PhD Ausio Pharmaceuticals, LLC by Larry and Leslie Nance and James and Judith Wilson. Medical Center University of Pennsylvania Chronic Myeloid Leukemia 4 W. Stratford May, Jr, MD, PhD 5 Hodgkin Lymphoma Research Portfolio is funded in part by Alex and Alexandra Mayes Birnbaum School of Medicine Janet Boggs, Kickin’ the Cancer Blues/The Liz Bohman Foundation, University of Florida, Hodgkin Lymphoma 5 Peartree Publishing A. Keith Stewart and Lazard Capital Markets. Shands Cancer Center Jorge Cortes, MD Mayo Clinic and Foundation Myeloma 6 6 Myeloma Research Portfolio is funded in part by the Carlson Family Susan M. O’Brien, MD University of Texas Foundation, James and Eleanor Delfino Charitable Trust, the Names Kathryn Vecellio University of Texas M.D. Anderson Cancer Center Aggressive Non-Hodgkin Family Foundation and The Springberg Charitable Fund. The Vecellio Group M.D. Anderson Cancer Center Lymphoma 7 James H. Davis, PhD, JD 7 Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded J. Fred Pritchard, PhD Human Genome Sciences, Inc. Indolent Non-Hodgkin in part by Ray Bromley and Friends, and William Kraft. Celerion 8 8 Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part Russell Enns, PhD Lymphoma Nancy Speck, PhD by Nonnie and John Barbey, Jay and Susan Clark, Andrew F. Gulli, Cepheid, Inc. Pediatric and Young Adult Timothy and Christine Lindenfelser, Jerry and Lois Rosenblum, University of Pennsylvania Blood Cancers 9 the Warne Family Charitable Foundation, David Weinstein, and an School of Medicine anonymous donor. Quality of Life 10 9 Pediatric and Young Adult Blood Cancers Research Portfolio is funded in part by Noah and Sandra Anderson, the Thomas and Agnes Carvel Targeted Therapy 11 Foundation, the Alverin M. Cornell Foundation, The Critchley Family, Therapy Acceleration Franklin American Mortgage Company, Hockey Fights Cancer, Karyn Research Fund, the Samuel Freeman Charitable Trust, and WaWa, Inc. Program 12 10 Quality of Life Research Portfolio is funded in part by Hildegarde D. endowment funds Waldenstrom Becher Foundation, Inc., The Cherry Picker Foundation, The Escher Macroglobulinemia Initiative 13 Foundation, the Hamill Family Trust, ICAP Services North America, LLC, The Douglas Kroll Research Foundation, Prasanna and Shraddha Malaiyandi, and an anonymous donor. 11 Targeted Therapy Research Portfolio is funded in part by the Fred J. The Bill Beattie Memorial GlaxoSmithKline Foundation – Jane Elissa/Charlotte Meyers Brotherton Charitable Foundation. Endowment Fund (Alberta) Gertrude B. Elion Endowment Endowment Fund Fund 12 Therapy Acceleration Program is funded in part by the Edward P. Evans Mary & Robert Bronstein The Rae Endowment Fund Foundation, The For Julie Foundation, Inc., The Lymphomaniacs, Memorial Fund GlaxoSmithKline, Inc. (Ontario) The Harry T. Mangurian, Jr. Foundation, Inc., Lance Meyerowich, Research Fund The Roderick Seward, Flossie Radcliffe & Helen M. Galloway Foundation, The Virginia Major Brooks Vrushali Ranadive Fellowship Fund and Jerry and Lois Rosenblum. Memorial Endowment Fund Jim Jacobs Leukemia Reich Endowment Fund 13 Waldenstrom Macroglobulinemia Initiative is fully funded by the Research Fund de Villiers Endowment Fund International Waldenstrom’s Macroglobulinemia Foundation and the The UFCW (Canada) Steven and Michele Kirsch Fund, an advised fund of the Silicon Valley The Rachel Kudish Fund Thomas M. Ford Memorial Fund Endowment Fund Community Foundation.

22 donors

The below listing is made up Industrial Alliance Pacific (IAP) Susan Lang Foundation Doctor’s Choice Pharmacy New York Community Bancorp of individuals, foundations and $100,000 – $499,999 International Waldenstrom’s Teva Oncology PS C Dominick’s Northrop Grumman corporations that generously Macroglobulinemia Foundation* Michael and Judy Thomas Elekta C Omnitech supported LLS’s mission during James L. Eichberg Foundation this fiscal year. Deborah Tobias* Fleming’s Prime Steakhouse Onyx Pharmaceuticals, Inc. PS ADP (JLEF) Robert Toner & Wine Bar The Party for a Cure Allos Therapeutics, Inc. PS C Joseph & Drenda Vijuk Foundation Jack A. Turpin The For Julie Foundation, Inc. Ping Y. Tai Foundation Amanda Wins Fund Joseph S. and Diane H. Steinberg Freeman $1,000,000 and above Charitable Trust* UnitedHealthcare Donald Porteous Astellas USA Foundation C Vistar Garden City Turkey Trot Regence BlueCross BlueShield Sydney and Isobel Kemper* Austaco, Ltd. – Taco Bell GCG of Oregon Neil Kishter* VITAS Innovative Hospice Care Laurie Adami and Ben Robertson* AutoCricket Corporation GEICO Reliant, an NRG Company Lazard Capital Markets LLC Wells Fargo The Beer Store Nonnie and John Barbey General Dynamics Information Ridgewells Rush Limbaugh Winston Partners Burlington Coat Factory Beattie Homes Ltd. Technology RMD Corporation Timothy and Christine Anonymous (2) Celgene Corporation PS R C The Blumenfeld Family General Services Administration Lindenfelser* SAC N PAC Edward P. Evans Foundation BMC Genoptix Medical Laboratory PS The Mansbach Foundation, Inc. SanDisk Corporation Genentech, Inc. PS R PP C Bristol-Myers Squibb Greater Saint Louis Community The Marge & Charles J. Schott Sedano’s Supermarkets Company PS $50,000 – $99,999 Foundation The Harry T. Mangurian, Jr. Foundation* Siemens Foundation, Inc.* BuildASign.com GSP Transportation Clyde Smith McGregor The Springberg Charitable Fund* The Joseph C. Sanfilippo CA Technologies Leon W. (Pete) Harman and LeAnn Pedersen Pope – Accenture Memorial Fund, an advised Sysmex America, Inc. California Community In Memory of Joan Kowing HCA fund of Saratoga Monte Sereno McGregor American Electric Power Todd McClintock Memorial Foundation* The HEADstrong Foundation Community Foundation* Amgen C Research Fund CareFirst BlueCross BlueShield Missouri Foundation for Health* Millennium: The Takeda Human Genome Sciences, Inc. Toyota Nike Paul and Helen Anbinder Oncology Company PS R C Carter’s, Inc. Jack’s Mannequin – Dear Jack The Victor E. & Caroline E. Schutte The Orokawa Foundation Stephen and Madeline Anbinder The Olive Garden Italian Cassidy Turley Foundation Foundation – Trust E Restaurant The Pamela B. Katten Memorial AutoTrader.com Citrix Systems, Inc. The Jake Wetchler Foundation WalMart Stores, Inc. The Paul E. Singer Family Leukemia Research Foundation Baker Botts, LLP Community Health Charities Kaiser Permanente PS Washington Gas Foundation* of Nebraska Pfizer, Inc. PS PP C The Beck Family Foundation John Kellenyi Washingtonian Magazine United Food and Commercial PVH Booz Allen Hamilton Dallas Saint Valentine’s Luncheon Laborers’ Charitable Foundation Workers International Union Wells Fargo Private Bank and Fashion Show Rally Foundation for Childhood Boscov’s Leechman Industries, Inc. Canada/TUAC Cancer Research* Wilson Farms, Inc. Deloitte LLP BTIG Leo W. & Lilyan E. Cole Fund United Food and Commercial The Robert H. Lyon Leukemia Anonymous (1) DialAmerica Carlson Family Foundation, Inc.* Workers Union (UFCW) Foundation Brian Levine The Douglas Kroll Research Cars Fighting Cancer Foundation Runner’s World Lighthouse Investment CN Partners, LLC Ed and H Pillsbury Foundation Rust Consulting, Inc. Comcast Spotlight LLS New York City Chapter $500,000 – $999,999 Salt River Pima-Maricopa Elbit Systems of America, LLC Board of Trustees Indian Community Community Health Charities Ernst & Young LLP of Florida Lundbeck Canada, Inc. Samuel Freeman Barclays F.M. Kirby Foundation, Inc.* Charitable Trust Community Health Charities Metro Richelieu, Inc. Pharmaceutical Funding PS PP of Minnesota Legend Novartis Pharmaceuticals GlaxoSmithKline Security Service Federal Metzger Law Group Corporation PS Community Health Charities The Greene Team Credit Union Michael C. Fina of New England PS Patient Services/Education Andrew F. Gulli Silicon Valley Bank Morris Levine Key Food Credit Suisse IHOP Stater Bros. Charities Foundation PP Public Policy The Critchley Family C Imagine a Cure for Leukemia The Steven and Michele Kirsch Gary Moy Campaign Fund, an advised fund of Silicon Deloitte Federal Government R Research Incyte Corp. PS New Media Strategies Valley Community Foundation* Services * Denotes multi-year commitment 23 donors (continued)

Amon G. Carter Foundation Berkshire Bank The Browery Presents Cavignac & Associates Coastal Construction Group $10,000 – $49,999 Noah and Sandra Anderson BERT SMITH & CO. The Brown Family CBRE, Inc. Coinstar CE and Jean Andrews Big Steaks Management, LLC Brown & Gould, LLP cCARE The Cole Foundation Annaly Capital Management, Inc. Mark Billings The Bruce, Elaine, and Holland CCL Label The Coleman Foundation 21st Century Insurance Company Hiler Family Anning-Johnson Company Biogen Idec C CED des Employees du secteur The CollegeBound Network ABB Foundation, Inc. Anthem Blue Cross and Alexandra Mayes Birnbaum Joe and Cynthia Bruno Industriel and Staten Island Parent ABM Janitorial Services- Blue Shield of Ohio Bisnow BT Conferencing, Inc. Celator Pharmaceuticals Corp. C The Colton Company Midwest, LLC AON The Blackstone Group Bull & Bear Golf Outing Cell Therapeutics PS C Columns Resource Group Ann Adams Foundation, Inc. Apache Corporation Blake Shelton Fans Jeff Burch Centene Charitable Foundation Adobe Systems, Inc. Combined Health Agencies Argy, Wiltse and Robinson, P.C. Bloomingdale’s Burris Construction Company, LLC Central Blood Bank Ben Aeilts Comcast ARIAD Pharmaceuticals, Inc. C Blue Apple Books Butler Family Foundation Centre de Formation de AFD Contract Furniture, Inc. L’alimentation & du Commerce Commerce Bank Don Armstrong Blue Buffalo Company Jeff Butts and Lisa Hale Affiliated Communications de Quebec Tim and Nancy Armstrong John Byrd The Community Foundation of Wisconsin, LLC Blue Canopy Group Centro – Charleen’s Angels for the National Capital Region Astex Pharmaceuticals C C. H. Guenther & Son, Inc. Affinion Group Blue Cross Canada Cerner Corporation Community Health Charities Atlas Signs C. Jay Moorhead Foundation Air Liquide Canada, Inc. Blue Cross and Blue Shield CGI of Arizona Atmel Corporation of Alabama C.J. Coakley Co., Inc. Air Products Chapin Davis Foundation Community Health Charities ATR International Blue Cross and Blue Shield CA Technologies Matching of California Air Products Foundation Charles A. Klein & Sons, Inc. Audi North Atlanta of Mississippi Gifts Program Community Health Charities Akerman Senterfitt The Charles T. Bauer Foundation of Colorado Audio Visual Services Group, Inc. blue moon fund CACI Alberto Culver Company Charlette Florence Trust Community Health Charities AVM, LP BMO Harris Bank Caesars Foundation Alexandra’s Team Chartis, US of Illinois B3 Solutions LLC BMW of San Antonio Café Elm Alexandria Real Estate Community Health Charities BNY Mellon Caisse Populaire Desjardins Chartwell Charitable Foundation Equities, Inc. Dean and Anna Backer of Iowa The Boal Family Canadienne Italienne R. Martin Chavez The Allender Family Baker Tilly Community Health Charities California Foundation for Stronger The Cherry Picker Foundation Foundation, Inc. Tim Banazek Bruce Bocina of Kansas & Missouri Communities Chevron Alliance Data Systems, Inc. Bank of America Alex and Janet Boggs Community Health Charities Dillon Cameron Chiaramonte Construction Allstate The Boston Foundation of Kentucky Bank of America Merrill Lynch Anthony Campbell Company Alto-Shaam, Inc. Boston Millennia Partners Community Health Charities Baptist Health South Florida Matthew Campbell Justin Chueh of Maryland The Altschul Foundation – BP Fueling Communities Barclaycard US Cancer Treatment Centers Citi Community Health Charities Reichman Memorial BP Products North America, Inc. Bare Escentuals of America Citi Corporate and of Michigan Alverin M. Cornell Foundation Barrett Family Foundation Brandon Pitzer Memorial Canucks for Kids Fund Investment Banking Community Health Charities Amadeus North America, Inc. of New York BASF, The Chemical Company Brayton Purcell, LLP Capital One Bank Jay and Susan Clark Ambitt Energy Community Health Charities Bass Pro Shops In Memory of Emerson B. Bridges Capitol File Magazine Clark Construction Group, LLC Ameren Corporation of South Carolina Lee Bates Bridgestone Americas Tire Capstone Advisory Group, LLC Cleary Gottlieb Steen & American Construction Co., Inc. Operations Hamilton LLP Community Health Charities BD Biosciences Carbide Concepts Company, LLC of Texas American Electric Power Bristol-Myers Squibb Company Carella, Byrne, Bain, Gilfillan, Bruce and Isobel Cleland BDO USA, LLP Canada C Community Health Charities American Family Care Cecchi, Stewart & Olstein Cleveland Society for Human of the Southeast BDT Capital Partners, LLC Broadway Cares/Equity Fights American General Life & Resource Management AIDS, Inc. Carfax Community Health Charities Accident Insurance Company Patricia Beattie Clifford Viner Family Foundation of Virginia Andrew Brock Carolina Aesthetic Plastic AMERICAN SYSTEMS Greg and Michelle Becker Surgery Institute Christopher Cline Compass Self Storage Peter and Janice Brock America’s Charities Brian and Lisa Bee – Spin 4 Alan Carp Clune Construction Company Bill Conley the Cure Ray Bromley & Friends Ames True Temper Donald and Linda Carter Coach Foundation Contemporary Electrical The Belvedere Cove Foundation/ Broward Health Amica Insurance Cromar Foundation Cascade Recovery, Inc. CoActiv Capital Partners Services, Inc. 24 Cookie Associates, LTD Deans Knight Capital Enterprise Holdings Foundation Frieze Harley-Davidson Gore Design Completions, Ltd. Heuberger Motors Bob Cooper CLL Research Fund Management Ltd. Enterprise Holdings, Inc. Froedtert Hospital The Grace J. Fippinger Foundation Highstar Capital Cora and John H. Davis Deltek Enterprise Products Company FTI Consulting Grant Thornton, LLP Hildegarde D. Becher Foundation Desert States Charitable Enterprise Rent-A-Car Fulbright & Jaworski, LLP Grassmere Foundation Foundation, Inc. Foundation Corporate Executive Board Epic Furniture Fair Graymeiren Holdings, LLC Al G. Hill, Jr. Deutsche Bank The Cortland Finnegan Epsilon Data Management, LLC G & T Sports Medicine Great American Cookies Hitachi Data Systems ARK 31 Foundation Daniel Devine Erie and Niagara Insurance Enrico Gaglioti Great American Insurance Group HITT Contracting, Inc. Costco The Dial Corporation, Association HM Life Insurance Company a Henkel Company Galen College of Nursing Great Charity Challenge Coty Prestige Ernst & Young Transaction Hockey Fights Cancer Dianon Systems Garden City Group Great Clips Calgary Coop Courtney Knight Gaines Advisory Services Hogan Lovells US, LLP Foundation Discount Tire Co. Gardner Family Trust Greater Los Angeles New Car The Escher Foundation Dealers Association The Hollander Foundation Crain Family Foundation Dixon Family Foundation GE Bright Lights John Esposito Greater Milwaukee Dwight Holloway Crane Fund for Widows Nick and Connie Djajich GE Capital ESPN980 Foundation, Inc. HOT 99.5 and Children DJO Global GE Foundation Excellence in Motivation, Inc. Rochelle Greenberg Houlihan Lawrence Cravath, Swaine & Moore, LLP DLA Piper, LLP General Dynamics Rob and Linda Faktorow Greenberg Traurig, LLP Jennifer and Doug Houser Credit Suisse Americas Albert Dombrowski General Motors LLC – Foundation F.A.L.L. Classic Metro Detroit Grousbeck Family Foundation The Howard Family Foundation Don C. & Diane S. Lake Family The Familant Family Bosa Grubich Cross Country Service Corp Genzyme Corporation PS Hoxworth Blood Center Doosan Corporation Research Fund Crowe Horwath, LLP The GEO Group, Inc. GTSI Corporation Huntington Bank Dow Electronics FarmerMac Crown Cork & Seal Company The GEO Group Foundation Glenn Gurr HVAC Concepts, Inc. Dragon Wolf Foundation, Inc. Harry Faulkner Cruise Industry Charitable George and Mary Josephine Haemonetics Corporation Hy-Vee, Inc. Foundation Dreyer’s Grand Ice Cream, Inc. Suzanne Fedder Hamman Foundation Hamill Family Trust John Hyland Cruise Planners/American Express Dun & Bradstreet, Inc. Fidelity Charitable Gift Fund George L. Shields Foundation, Inc. The Handlery Foundation IBC Bank CSC Consulting, Inc. Norma Dunn Fiesta Mexicana George’s Neighborhood Grill Jeff and Deb Hansen IBM Cub Foods Michael Dweck Fifth Third Bank Georgia Power Foundation, Inc. Harari Family Charitable Trust IBM Employee Services Center Michael Cunningham E Construction Group, Inc. Findlay Cadillac The Gerald and Paula McNichols Harkins Builders ICAP Services North America, LLC DaHunt for the Cure, LLC EasyCanvasPrints.com Finnegan, Henderson, Farabow, Family Foundation Harrah’s Foundation Garrett & Dunner, LLP Idan’s Fans Dairy Farmers of America eBioscience, Inc. C Giannoulias Hospitality Harris Corporation First Service Credit Union IMG Dallas Stars Foundation Ed Voyles KIA Gibson, Dunn & Crutcher, LLP Harrisburg Magazine FIS In Memory of Barbara Jules Dan Wolf Automotive Group Edgar A. Thronson Gila River Casinos Harry Harrison Foundation, Inc. Fitzgerald Family Foundation Independence Blue Cross Dana-Farber Cancer Institute Peter and Ann Gilbert The Harry & Jeanette Weinberg Edge Construction Annie Flaig Independent Health Danaher Foundation Gish, Sherwood & Friends, Inc. Foundation, Inc. Edith M. Schweckendieck Trusts Flippers Express Car Wash Danford Foundation Give with Liberty Harry C. Moores Foundation Edward G. & Kathryn E. Mader FMC Corporation Glimcher HazMat Environmental Group, Inc./ DARCARS Foundation FMI International Global Fulfillment Solutions Kenworth of Buffalo Datacomm Services, LLC EFESTÉ Winery Foley & Lardner, LLP Global Income Investments, LLC Russell and Sadonna Head Pharmaceutical Funding The David and Patricia Giuliani The Eli & Edythe Broad Foundation Family Foundation Fondation GDG The Gold Diggers, Inc. HealthONE Legend Eli Lilly and Company C David Booth Foundation on behalf Foundation Beyond Belief Jane Goldman Heartland Blood Centers of Hockey Ministries International Elmwood Country Club PS Franklin American Mortgage Goldman, Sachs & Co. H-E-B Patient Services/Education David Yurman, Inc. EMC2 Company PP Public Policy Golf for Kids The Hedinger Family Foundation Davis Polk Emergent BioSolutions C Frazier & Deeter, LLC C Campaign Gerry Golub Dave Heller Emerson Process Management Fred J. Brotherton Charitable DC Chartered Health Helsinn Therapeutics, Inc. C R Research Foundation John Goodish DCM The Enrichment Foundation * Denotes multi-year commitment 25 donors (continued)

Infosys Public Services Kal Tire Jack and Peggy Lewis Rocco and Roxanne Martino Mitsubishi Power Systems, Inc. Gary and Amy Norcross Institute of Transfusion Medicine / Daniel and Susan Kane Steven Lieblich Mary & Michael Levine Mizuho Corporate Bank North Sails LifeSource The Karches Foundation Lightning Foundation, Inc. Charitable Fund Patricia Moats Northrup Grumman Systems Insulators International Health Karyn Research Fund Lindquist Family Foundation Mary Pillsbury Foundation Modell’s Sporting Goods Corporation Hazard Fund Kass Family Foundation Lisa J. Leder Family Marylou’s Coffee Lori Mody Northside Hospital Integrys Energy Services Adam Katz Foundation, Inc. Mark Mason Momentum Jaguar-Land Rover NPL Construction Company International Lease Finance LIST Innovative Solutions Maurice Cares Southwest Houston Offshore Sailing School Corporation Christopher Kearns Joseph Littenberg Maxim Group, LLC Momentum Microsystems, Inc. The Offterdinger Family The International Society The Keith Hamm Foundation Ken Gardiner Model Maker Peter and Tina Locke MAXIMUS Foundation Peter Moran The Ohio State University Iroquois Middle School James Cancer Hospital Kent’s 5K Run Lockheed Martin Corporation Mayo Foundation for Medical Ron and Adrienne Morgan ISC Sales, LLC Information and Research & Solove Research Institute The Kerins Family Lockheed Martin Missiles Morgan Borszcz Consulting The Isenberg Family and Fire Control – Dallas Mary E. McCaul OHSU Charitable Trust Kickin’ The Cancer Blues – Morgan, Lewis & Bockius LLP The Lois Pope Life Foundation Casey McGlynn Diane Oldach ITG The Liz Bohman Foundation Morgan Stanley Albert and Suzanne Lord McKenna Long & Aldridge LLP Walter Oliver Ivie & Associates, Inc. King & Spalding, LLP MorganFranklin Corporation Lord & Taylor Meadow Gardens Ladies Club OnCore Manufacturing J. Crew Kirkland & Ellis Foundation Morrison-Minton Family Trust Services, LLC L’Oréal USA Meadowlands Country Club J.B. Fuqua Foundation Kohl’s Morristown Memorial Hospital OneSource Distributors, LLC The Lotz Family Foundation Mechanical, Inc. J.T. Tai & Co. Foundation, Inc. Kolache Factory Mount Gay Rum Oracle Corporation Luby’s Fuddruckers MedImmune, Inc. C James and Eleanor Delfino Stanley Korshak Patrick Mucci Orbital Engineering Restaurants, LLC Megan’s Wings, Inc. Charitable Trust KPMG, LLP Elizabeth Mungo Ortho-Clinical Diagnostics, Inc. Lunardi’s Supermarket, Inc. Sanjay and Sangeeta Mehrotra Jarden Westchester Triathlon Charles and Lynda Kraemer Murphy-Hoffman Company Oscar, Inc. Lundbeck, Inc. C MEMC Electronic Materials, Inc. Jared Coones Pumpkin Run/Walk Mark and Christine Kraemer The Najim Family Foundation Osprey Fund Lukas Lundin Memorial Healthcare System The JBG Companies William Kraft Names Family Foundation Peter O’Sullivan M&I Bank Menchie’s Frozen Yogurt JDP Mechanical, Inc. Warren Kreter Larry and Leslie Nance O’Sullivan Plumbing M&T Bank William Mentlik The Jeannette and H. Peter Kritchman Family Foundation Inc. Nartel Family Foundation OTG Management Kriendler Charitable Trust M&T Charitable Foundation Mercedes-Benz USA, LLC The Kroger Co. National Journal Ourisman Chantilly Imports, Inc. The Jim Jacobs Charitable Mack Madness, Inc. KST Data Inc. Jim and Carol Mercier National Philanthropic Trust Foundation Julio Maclay Par For A Cause LabCorp MERCK & Co., Inc. C National Rural Utilities Jim Koons Automotive Companies Macquarie Securities Parents Against Leukemia Ladish Co. Foundation Merrill Lynch Private Banking Cooperative Finance The Jim Quay Memorial Fund Macy’s, Inc. & Investment Group Corporation (CFC) Emily Park Mike and Kathy Ladra Jobson Sailing Major Hyundai Daniel Metzger Dan and Martha Nealon The Park Foundation LaFontaine Automotive Group Johnson & Johnson Prasanna and Shraddha Michael Sweig Foundation Jeffrey Nedelman Park Place Motorcars Dallas David Laidley Jones Day Malaiyandi* Michelle Lunn Hope Foundation NetApp Patti Robinson Kaufmann Latham & Watkins, LLP First Connection Sally and Ralph C. (Red Dog) Matthew Mallgrave Microsoft The Netter Family Foundation Jones John Lauto Paul Hastings The Mammel Family Midwest Cancer Care – HCA New York Knights of the Grip Jordan Valley Medical Center Lawrence Medical Products – Foundation Midwest Health System Nassau, Inc. Pegasus Capital Advisors, LP Move Around IV Buggy Joseph R. Daly Foundation Management and Training Mike Hunter’s Team The New York Mets Foundation, Peoples Natural Gas Learjet Employees Care Fund Consultants, Inc. (MTCI) Joslins Jewelry Milbank, Tweed, Hadley & Inc. PEPCO Holdings, Inc. Greg and Nancy Ledford Peter and Gina Manos The June and Cecil McDole McCloy LLP Nexen Petroleum USA, Inc. Peraino’s Jewelers Charitable Fund Legal Placements, Inc. Marriott International Edward Miner Nicholas Family Foundation Performance Food Group Kaelin Family Captain’s Cup Paul Leinwand David and Joann Marrs Mr. and Mrs. Barry Minkoff Nidec Motor Corporation Perry Ellis International, Inc. Gerald Kafka and Rita Cavanagh The Len-Ari Foundation, Inc. Marsh Supermarkets, Inc. Mr. and Mrs. Rusty Minkoff NMMA Perry Homes Stanley and Sandra Kahan Leon S. Peters Foundation Bruce D. and Electra C. Martin Suzy Minkoff Guy and Linda Nohra Sheldon and Donita Petersen

26 PGT Trucking, Inc. Ray Catena Auto Group Roper St. Francis Healthcare Peter Scialla Southstar Energy Services, LLC Sweet Ovations, LLC Pharmaceutical Care Ronald Raymond Jerry and Lois Rosenblum Seagate Technology, LLC Southwest Convenience Stores Sylvan & Ann Oestreicher Management Association Foundation, Inc. Real Estate One Foundation RPA Advisors, LLC Seattle Genetics, Inc. C Spangenberg Family Foundation Philadelphia Multiple Myeloma Red Robin – Lehigh Valley RR Donnelley Isador S. Segall Trust Richard Spayde Synopsys, Inc. Networking Group Restaurant Group Tap Cancer Out RREEF Peter Selman Spectrum Pharmaceuticals, Inc. PS Philip E. Fess Family Foundation Redman Triathlon Ruby’s Diner, Inc. Sempra Employee Giving Network Stephen and Bonnie Spiegle Target PhRMA C Redwood Regional Medical Group Paul Russo Sempra Energy Foundation Mark and Carol Spisak Paul Taubman The Phyllis M. Coors Foundation Regions Bank Jeff and Pat Sachs Serco Sprint TCDI Piedmont Healthcare Dr. Faisal Rehman Sail America Sessions, Fishman, Nathan SRA International TCF Bank Pillsbury Winthrop Shaw Roberta Reitzes & Israel, LLC TE Connectivity Ltd. Pittman, LLP Sailing for a Cure Foundation SSQ Assurance Generales Reliable Churchill C. Kevin Shannahan Team Financial Managers Marie E. Pinizzotto, MD Sailing World St. Joseph’s/Candler and Carol Ammon Reliant Energy Foundation John and Lauren Salata Shawn Burr Foundation St. Juste Management Corp. Team Makai Pinnacle Capital Mortgage Reliant Park Sallie Mae, Inc. Heather Shemilt St. Luke’s Mountain States Team Marge Corporation Rels Sam J. Frankino Foundation Sherrard Kuzz, LLP Tumor Institute Teneo Strategy Plaid Pantries, Inc. James Resnick Sam Swope Auto Group, LLC The Shimkin Foundation State Street Corporation Elizabete Terminella Planned Systems The Rhoda and David Chase Sam’s Club Philip Shipp Susan B. Stearns Terumo BCT, Inc. International, Inc. Family Foundation, Inc. Samuel C. Cantor Charitable Trust Shiseido Americas Corporation Stefan Belanic’s Legacy Texas Instruments, Inc. The PNC Financial Services Group Rhulen Rock Hill Run & Ramble The Samuel P. Mandell Foundation ShopRite Step by Step Charitable Thaler Machine Co./James Polk Bros. Foundation Michael Richman Foundation, Inc. Construction San Diego Gas & Electric Sidley Austin, LLP Popular Community Bank Richman Asset Management, Inc. Deborah Stephen The Fan 97.1 San Diego State University, The Sidney, Milton and Leoma The Portmann Family Riemer & Braunstein, LLP College of Business Simon Foundation Sterling Mets LP The Moorings Charitable Fund Rio Grande Cancer Foundation Administration Sigma Chi Fraternity Sterne Kessler Goldstein Billie Thomas Poses Family Foundation RoadID, Inc. The San Francisco Foundation Silicon Valley Bank & Fox P.L.L.C. Thomas & Herbert Consulting, LLC Powell Industries The Robert Berne Foundation San Par Golf Tournament John Silvestri Steven A. & Alexandra M. Cohen Thomas and Agnes Carvel Practice Fusion Foundation Robert E. Gallagher Thomas Sandell Howie Simon Foundation Pray Family Foundation The Steven M. Perez Foundation Charitable Trust Sandra Atlas Bass and Edythe Gilbert and Alison Simonetti Thompson Habib Denison (THD) Presbyterian Cancer Center Scot Stevens The Robert I. Lappin Foundation & Sol G. Atlas Fund, Inc. Jim and Kathy Simpson Tiber Creek Partners, LLC John and Monika Preston Stonebridge Companies Robert Michael Educational Sanofi Aventis PS Simpson Thacher & Bartlett, LLP Title Associates Price Chopper Supermarkets Institute, Inc. SAP America, Inc. Strategic Wealth Management The TJX Companies, Inc. Siuslaw Bank Advisors, LLC PricewaterhouseCoopers, LLP Mrs. Edgar A. Robinson Sarver Charitable Trust Andy Todd Skunk Train Stratford Hospitality Procter & Gamble Stewart Robinson Sasco Foundation Toll Brothers, Inc. SMART Modular SunDun Office Refreshments Prudential Andrew Roby Savannah Chatham Imaging Technologies, Inc. Sunesis Pharmaceuticals, Inc. C PVH Foundation, Inc. The Roderick Seward, Flossie Thomas and Laurie Saylak Douglas A. and Phyllis Smith Radcliffe & Helen M. Galloway Sunflower State Enterprises, Inc. Quad/Graphics, Inc. John Scarpa Elaine Smith Foundation Sunrise Senior Living The Quinn Law Firm Melodie Scharf William Smith Pharmaceutical Funding Shirley Axtmayer Rodriguez SunTrust Banks, Inc. Quintanilla Management Company Bradley Scher Smith Production, Inc. Legend Peter and Lynn Rogers Survivor Team 2011 Quintiles Nancy C. and Richard R. Rogers Stephen Scherr Barry and Meredith Snader Susan Mott Webb PS Patient Services/Education Rahr Malting Co. Rogers Family Foundation* Michael and Susan Schuldes Soccer Against Leukemia Charitable Trust & Lymphoma PP Public Policy Ralph Lauren Corporation Rollin M. Gerstacker Foundation Harvey Schwartz Sutherland Foundation Southeast Nebraska Cancer C Campaign Rapid Rehab of Illinois Ronald and Mary Pott Family Scott Schweignhauser Swanson Group, LTD Center R Research Ratopia Charity Fund Foundation John and Martha Schwieters Southern Company Michael and Elizabeth Sweeney * Denotes multi-year commitment 27 donors (continued)

Towers Watson The Victor E. & Caroline E. Schutte Williams & Connolly, LLP Tommy Cleaver* Kim Heemstra Foundation – 1959 TPG Capital LP James and Judith Wilson Top Campaign Fundraisers Lindsay Drew Coulter Angela Helmer TRANSWESTERN Victory Brewing Company Bernie Winnicki Justin Chueh Eric J. Henry TRIB Total Media The Virginia Sheldon Jerome WIVB-TV Citrix Systems Wayne Hogrefe Foundation Schools that have raised The TriLink Team WMZQ more than $25,000, individuals Coach, Inc. Kieran Holohan Vitol Group Trion Group, Inc. WTOP Radio who have raised more than Gary Cohen John Park’s Champions The W. O’Neil Foundation $50,000 or company/teams Troutman Sanders, LLP WUSA9 The Critchley Family Jonathan Juravich & Team J Waddell & Reed Kansas City that have raised more than TRUiST Marathon with Ivy Funds Yahoo! Employee Foundation $100,000 within one season DCA Capital Partners Dan Kaplan to support LLS’s mission. The Truland Group Inc. Gloria Somerville Wagner Mina Yanney Deloitte LLP John Kellenyi Trusted Choice Independent Yoder Industries Dawn Delvo KForce John F. Waitz Patricia Abboud, MD Insurance Agents of Illinois Eric, Tamara and Nicholas Yollick Bygie Dixon Erin Kirkpatrick Maura and Stephen Walsh Amy P. Abernethy, MD Tube City IMS Your Cause LLC Michelle Dodd Kiven, Kotler, Lieberman, Ted Wang ADP Turner Construction John and Adelaide Zabriskie Suzanne Donaldson Fox, Joffe, Goldschmidt Warne Family Charitable Austaco, Ltd. – Taco Bell TVEyes, Inc. & Kepes Team Foundation Zenobia Therapeutics C Dan Dortic Kelly Bar-Or Rory Koslow UBS Financial Services WASH-FM Ziolkowski Patent Solutions Tam Driscoll Barclays KPMG UCSD/Sharp BMT Program Washington Business Journal Group, SC Michael Effron Beckendorff Junior High School Matt Krueger Ultimate Software Bill and Denise Watkins Joseph Zvesper Daniel Einhorn Benjamin’s Team Rick Kuper Mark Unatin Family Wawa, Inc. Anonymous (17) Elbit Systems of America Bennett’s Buddies Ryan LaFontaine Union First Market Bank Wawanesa Insurance Ernst & Young, LLP Becky Berthelot Laurie LuLu and her Entourage United HealthCare Services, Inc. WBIG Anthony Falco Bettysport’s Team Ruben Ralph Lawrence United Martial Arts Center WBNS 10TV Harry Faulkner Briarcliff Biogen Idec Eric Lebenson Web Marketing Associates FIS United States Steel Corporation Elaine Bissias Brian Leech WebMD Health Foundation, Inc. Marc Friedenberg United Way Canada The Blackstone Group The Lymphomaniacs WebMD, LLC Vicky Garcia University of Illinois Brad Blumenfeld Lauryn Maes Wechsler/Marsico Associates Genentech, Inc. Alpha Tau Omega Gamma BMC Eileen Mannion & Team Trinity Zeta Chapter Christopher Weiler Karin Gifuni Zumwalt Christina Bold George Mavrakis The University of Kansas David Weinstein Glamour Team Hairy Cancer Center Corie Boldt Casey McGlynn Wellmark Foundation Rebecca Glasgow University of Mississippi Terry Boston Rahul Mehra, MD Wells Fargo Foundation Goldman Sachs Medical Center Cancer Institute John Bowman Craig Mestel Wendco of Central PA, Inc. Heather Good UPMC Jason Brennan Lance Meyerowich West Marine Google UPS James D. Burgess Michael C. Fina West Penn Allegheny Jasmine Graham US Sailing Health System Burlington Coat Factory Microsoft Kina Grannis Utica Community Schools Westchester County Detectives CA Technologies The Mighty Molars Nelum Gunewardane Vaden Automotive Group Association, Inc. Pharmaceutical Funding Joe Caloggero Millennium: The Takeda Legend Janice Gunlund Valenti Mid-Atlantic Western Dental Services, Inc. Robert “Spider” Cantley Oncology Company Management, LLC Tom Gustafson White Allen Carter’s Dr. Douglas Miller Valero Energy Corporation PS Patient Services/Education Brianna Haag The Whitney Foundation Christy Cashman Dave Moran Vanderbilt-Ingram Cancer Center PP Public Policy Nancy Hagood John Willian Celgene Corporation Sara Morris Kathryn C. Vecellio C Campaign Dr. Paul Hamlin William E. Carter Company CenturyLink Sabrina Mosseau Verizon Business R Research Meghan Haven-Buske The William J. Shaw Family Dave Cherry & GLC50K Daniel L. Moyer Foundation, Inc. * Denotes multi-year commitment 28 legacy circle

Paul Murphy Skippy’s Team 2.0 Keith Williams Legacy Circle honors those who Franklin Gillespie* Sharie Phillips* Jerry Nabhan Brian Sladek Kirsa Williams designate LLS as a beneficiary Edna Gilpin* John Pilat* of their will, trust, retirement NARS Stater Bros. Charities Steve Wohlford account or insurance policy, Nathan Greenberg* Kathy Plank Manu Nathan Victoria Slocum Chuck Wurster or fund a charitable gift annuity. Paul and Beryl Greetin* Cecil and Ada Powers* We list our newest members Gary Norcross Verr Soltes Pam Yanis Rebecca Gross* David and Linda Pressley below along with those whose Novartis Pharmaceuticals, Inc. Tania Srouji Ryan Young bequests of $10,000 or more Alfred Haffner* Alan Propst* Oak Point Elementary School Boo Staley Katie Youngblood were received this year. Sharon Hailey Ronald Reinhagen* Fannie O’Donnell Sue Krzesinski Stanczak Martha Harper* Ruth Repko* Rose Accardi* Rick Olszewski Delbert Stapp Lauren Hart* Alice Richards Petrina Aguilar Dr. Anantanarayan Padmanabhan Tony Stayman Judith Helfant* Elizabeth Rockefeller* Mary Albright Marc Paolicelli Chuck Steeg Edward Henderson William Scanga Joseph Arnold* Partners For A Cure Livi Suarez, Esq. Arlene Hynes* Richard Schneyer Lorae Aumack* Partners Mortgage Brittany Tallon Edith Ingram* Harold and Phyllis Schwend* Lorraine Azrak* Nick Pepe Team Blumenfeld & Lyle Jaeger Faith Ann Searle* Charles David Barton Sarah Pepper Team Waterman Ivy Jerrard Catherine Setar* Florence Bevan* Julie Peterson Team WillyK Donald Johnson* Marilyn Shanholtz* Betty Birk* Pfizer, Inc. Gene Thomas Elizabeth Johnston* Anthony Simonetti Roy and Barbara Bouque* David Pollak Amanda Tiede Mary Jorgenson* Gertrude Slifkin Marjorie Bundrock* Zachary Potter Ruth Myers Tresnak Kirk Kaszak Mr. and Mrs. Paul W. Snyder Leatrice Cane* PricewaterhouseCoopers, LLP Mervyn Tugendhaft Ruthe Katz* Geri Sawyer Standfield* Tom and Chris Carleton PVH The V Team Ethel Kelly* Inez Starr* Michael Carter Suzzanne Thomson Quintero Kristi Vincelette Catherine Kinser* Betty Strucker* Antoinette Chesere* Rosa Raney Beth Viney Maria Kitzmiller* Neil Stuhr* Ted Christiansen Riders of the Storm Vistar Ellen Tobey Klass Bruce Swartz* Elise Church* Tim Robey VITAS Innovative Hospice Care Mildred Kleid Kelvin and Mary Thurman Cynthia Clark Brian Ross Kris Vogt Gail Kromer Harriet Troyan* Samuel Cohen* Roger Royse Fe Vorderlandwehr Frances Lau Lawrence Turner* Margot Cole and Seymour Falik Erin Zammett Ruddy Waddell & Reed Seymour Lavine* A. Kent and Sara Weymouth Marie Comodo* Matthew F. Sacco Mary Pillsbury Wainwright* Cheryl Lewington April White Beatrice Cuneo* SanDisk Corporation Brian Walsh Helen Lippert* Arthur Wiczko* Velid Dag* Colonel Donald E. Schaet Walt Whitman High School Catherine Maas* Sandy Willis Helen Dao USMC (Ret.) Walter Johnson High School Hertha Malz* Janet Wishnetsky Winifred DaVia* Meryl Schrank Louise Warner Brian Marsh* Loren Woerner Shirley Davidner Sheila Schroeder Caleb Warren Sherrill Martin Ellen Wood* Joanne Davis Security Service Federal Brian Waterman Michael Massius* Mary L. Worthy Credit Union Frederick Dibble* Watertown Middle School James Morris* Dale Wright* Eric Shanaberger Margaret DiDonato* Johnna Watson & Team Eli Carol Parker* James Zerjav* Jeb Shell Nelson Doland* Wells Fargo Margaret Patterson* Jay Zink Willa Sheridan Peggy and Margaret Dupaquier* Christie White Nancy Pechar Anonymous (5) Silicon Valley Bank Hubert Erickson* William Mason High School Pasquale Petti Kathy Simpson Cedric Williams Alejandro Garcia * National Man & Woman of the Year * Deceased 29 independent auditors’ report

The Board of Directors The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated statement of financial position of The Leukemia & Lymphoma Society, Inc. (LLS) as of June 30, 2012, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended. These consolidated financial statements are the responsibility of LLS’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. The prior year summarized comparative information has been derived from LLS’s 2011 consolidated financial statements and, in our report dated September 15, 2011, we expressed an unqualified opinion on those statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of LLS’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2012, and the changes in its net assets and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.

September 21, 2012 New York, New York

30 consolidated statement of financial position The Leukemia & Lymphoma Society, Inc. / June 30, 2012 (With comparative amounts at June 30, 2011) (In thousands)

2012 2011 Assets Cash and cash equivalents $ 25,972 $ 17,866 Prepaid expenses and other assets 6,716 5,171 Legacies and contributions receivable, net (note 2) 5,413 19,614 Investments (note 3) 184,084 181,876 Fixed assets, less accumulated depreciation and amortization of $11,374 and $8,606, respectively 6,854 5,413 Total assets $ 229,039 $ 229,940

Liabilities and Net Assets Liabilities: Accounts payable and accrued expenses $ 20,196 $ 17,715 Deferred revenue 17,737 17,241 Grants payable (notes 4, 5, and 6) 73,966 71,579 Total liabilities 111,899 106,535

Commitments and contingencies (notes 4, 6, and 8)

Net assets (note 9): Unrestricted 101,620 95,108 Temporarily restricted 12,163 24,405 Permanently restricted 3,357 3,892 Total net assets 117,140 123,405 Total liabilities and net assets $ 229,039 $ 229,940

See accompanying notes to consolidated financial statements.

31 consolidated statement of activities The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2012 (With summarized totals for the year ended June 30, 2011) (In thousands)

Temporarily Permanently Total Unrestricted restricted restricted 2012 2011 Revenue Campaign contributions $ 262,114 $ 68,041 $ 257 $ 330,412 $ 314,044 Less direct donor benefit costs (39,173) – – (39,173) (38,070) Net campaign contributions 222,941 68,041 257 291,239 275,974 Legacies 3,165 1,884 – 5,049 7,736 Donated services (note 1) 5,328 – – 5,328 5,983 Net interest and dividend income (note 3) 2,057 84 11 2,152 2,463 Net (decrease) increase in fair value of investments (note 3) (7) (212) 64 (155) 15,283 Grant refunds 1,477 – – 1,477 1,748 Net assets released from restrictions/redesignation 82,906 (82,039) (867) – – Total revenue 317,867 (12,242) (535) 305,090 309,187

Expenses (note 10) Program Services: Research 73,512 – – 73,512 71,985 Patient and community service 115,727 – – 115,727 109,496 Public health education 44,772 – – 44,772 44,197 Professional education 8,785 – – 8,785 7,979 Total program services 242,796 – – 242,796 233,657 Supporting Services: Management and general 24,869 – – 24,869 23,051 Fund raising 43,557 – – 43,557 42,367 Total supporting services 68,426 – – 68,426 65,418 Total expenses 311,222 – – 311,222 299,075 Change in net assets before foreign currency translation adjustment 6,645 (12,242) (535) (6,132) 10,112 Foreign currency translation adjustment (133) – – (133) 320

Change in net assets 6,512 (12,242) (535) (6,265) 10,432

Net Assets

Beginning of year 95,108 24,405 3,892 123,405 112,973 End of year $ 101,620 $ 12,163 $ 3,357 $ 117,140 $ 123,405

See accompanying notes to consolidated financial statements. 32 consolidated statement of functional expenses The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2012 (With comparative totals for the year ended June 30, 2011) (In thousands)

Program Services Supporting Services Direct Donor Patient and Public Management Total Benefit Costs community health Professional and Fund Research service education education Total general raising Total 2012 2011 2012 2011 Awards and grants $ 54,527 $ – $ – $ – $ 54,527 $ – $ – $ – $ 54,527 $ 49,906 $ – $ – Therapy acceleration program (note 6) 13,871 – – – 13,871 – – – 13,871 17,895 – – Financial aid to patients – 3,057 – – 3,057 – – – 3,057 5,579 – – Co-pay assistance (note 5) – 45,961 – – 45,961 – – – 45,961 37,947 – – Donated services 1,150 4,178 – – 5,328 – – – 5,328 5,983 – – Salaries 1,972 28,845 17,498 4,588 52,903 8,034 9,903 17,937 70,840 67,772 – – Employee benefits and taxes(note 7) 276 7,755 5,195 1,303 14,529 2,433 3,633 6,066 20,595 20,131 – – Occupancy (note 8) 42 3,400 2,522 675 6,639 1,066 1,456 2,522 9,161 8,801 – – Insurance 9 262 135 19 425 59 107 166 591 570 – – Telephone 35 1,214 918 136 2,303 307 988 1,295 3,598 3,692 – – Travel 94 1,403 1,082 293 2,872 613 678 1,291 4,163 3,614 9,801 10,500 Printing and supplies 197 2,615 5,413 413 8,638 3,997 8,489 12,486 21,124 22,385 6,867 6,294 Equipment rentals and maintenance 19 1,026 598 153 1,796 279 427 706 2,502 2,509 – – Postage and shipping 9 921 3,418 110 4,458 1,604 5,727 7,331 11,789 13,322 – – Meetings 633 1,976 803 138 3,550 394 411 805 4,355 3,446 11,129 10,266 Professional fees 607 10,531 5,471 535 17,144 4,982 10,395 15,377 32,521 30,426 3,682 3,529 Miscellaneous 26 1,647 1,030 295 2,998 754 719 1,473 4,471 3,021 7,694 7,481 Depreciation and amortization 45 936 689 127 1,797 347 624 971 2,768 2,076 – –

Total expenses $ 73,512 $ 115,727 $ 44,772 $ 8,785 $ 242,796 $ 24,869 $ 43,557 $ 68,426 $ 311,222 $ 299,075 $ 39,173 $ 38,070

See accompanying notes to consolidated financial statements.

Expenses

Research 23.6% Patient and Community Service 37.2% Public Health Education 14.4% 22% Professional Education 2.8% Total Program Services 78.0%

Management and General 8.0% Fundraising 14.0% 78% Total Supporting Services 22.0%

Total Expenses 100.0%

33 consolidated statement of cash flows The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2012 (With comparative amounts for the year ended June 30, 2011) (In thousands)

2012 2011 Cash flows from operating activities: Change in net assets $ (6,265) $ 10,432 Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities: Net decrease (increase) in fair value of investments 155 (15,283) Permanently restricted contributions collected (257) (105) Depreciation and amortization 2,768 2,076 Increase (decrease) in allowance for uncollectible accounts 40 (426) Changes in operating assets and liabilities: Prepaid expenses and other assets (1,545) (464) Legacies and contributions receivable, net 14,161 (771) Accounts payable and accrued expenses 2,481 1,267 Deferred revenue 496 301 Grants payable 2,387 (9,001) Net cash provided by (used in) operating activities 14,421 (11,974)

Cash flows from investing activities: Purchases of fixed assets (4,209) (2,357) Purchases of investments (94,729) (49,023) Sales of investments 92,366 59,919 Net cash (used in) provided by investing activities (6,572) (8,539)

Cash flows from financing activities:

Permanently restricted contributions collected 257 105 Net cash provided by financing activities 257 105

Net increase (decrease) in cash and cash equivalents 8,106 (3,330) Cash and cash equivalents at beginning of year 17,866 21,196 Cash and cash equivalents at end of year $ 25,972 $ 17,866

See accompanying notes to consolidated financial statements.

34 notes to consolidated financial statements The Leukemia & Lymphoma Society, Inc. / June 30, 2012 (with comparative amounts as of and for the year ended June 30, 2011)

1. Organization and Significant Accounting Policies Summarized Financial Information The consolidated financial statements are presented with 2011 summarized or comparative Organization information. With respect to the consolidated statement of activities, such prior year information The Leukemia & Lymphoma Society, Inc. (LLS) is an international not for profit health agency is not presented by net asset class and, in the consolidated statement of functional expenses, dedicated to seeking the cure of leukemia, lymphoma, Hodgkin’s disease, and myeloma 2011 expenses by object are presented in total rather than by functional category. Accordingly, and improving the quality of life of patients and their families. LLS’s principal activities include: such information should be read in conjunction with LLS’s 2011 consolidated financial statements awarding research grants; facilitating psychosocial support groups; providing financial aid from which the summarized information was derived. to patients; answering phone requests for blood cancer information made to LLS’s Information Subsequent Events Resource Center; and disseminating educational information about blood cancers in the form LLS evaluated subsequent events after the consolidated statement of financial position date of publications, internet sites, conference calls, and symposia sponsorship for both the medical of June 30, 2012 through September 21, 2012, which was the date the consolidated financial community and the general public. statements were issued, and concluded that no additional disclosures are required. Tax Exempt Status Net Asset Classifications LLS qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) To ensure observance of limitations and restrictions placed on the use of resources available to LLS, and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). funds that have similar characteristics have been classified into three net asset categories as follows: Additionally, since LLS is publicly supported, contributions to LLS qualify for the maximum charitable contribution deduction under the Internal Revenue Code. Unrestricted net assets: Consist of funds that are fully available, at the discretion of LLS’s Board of Directors, for LLS to utilize in any of its programs or supporting services. The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific disbursement requirements are met. time period and/or purpose. LLS recognizes the effect of income tax positions only if those tax positions are more likely than Permanently restricted net assets: Consist of funds that contain donor-imposed restrictions not to be sustained. Income generated from activities unrelated to LLS’s exempt purpose is subject requiring that the principal be invested in perpetuity and that only the income be used except to tax under Internal Revenue Code Section 511. LLS did not recognize any unrelated business where donor specified. Income earned on these funds are recorded as temporarily restricted income tax liability for the years ended June 30, 2012 and 2011. net assets and are released from restriction when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board-approved spending Principles of Consolidation policy (note 9). The accompanying consolidated financial statements include the accounts of LLS, which encompasses the Home Office of LLS and its fifty six chapters in the United States, LLSC and its Foreign Currency Translation five chapters in Canada, and LLS’s not for profit affiliates, The Leukemia & Lymphoma Society LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency impact of the Research Programs, Inc. and The Leukemia & Lymphoma Society Research Foundation. translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment All significant intercompany and intra-LLS accounts and transactions have been eliminated in the consolidated statement of activities. in consolidation. Fair Value Measurements Estimates Fair value is defined as the exchange price that would be received for an asset or paid to transfer The preparation of the consolidated financial statements in conformity with generally accepted a liability (an exit price) in the principal or most advantageous market for the asset or liability accounting principles requires LLS’s management to make estimates and assumptions that affect in an orderly transaction between market participants at the measurement date. The three levels the amounts reported in the consolidated financial statements and accompanying notes. The of the fair value hierarchy are as follows: significant estimates made in the preparation of these consolidated financial statements include Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities the fair value of alternative investments, the allowance for uncollectible accounts, and the allocation that a reporting entity has the ability to access at the measurement date. of expenses. Actual results could differ from those estimates. Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset Risks and Uncertainties or liability, either directly or indirectly. LLS invests in various investment securities. Investment securities are exposed to various risks Level 3 unobservable inputs for the asset or liability. such as interest rate, fluctuations in market security values, and credit risks. Due to the level of risk LLS follows the provisions of Accounting Standards Codification (ASC) 820, Fair Value Measurements associated with certain investment securities, it is at least reasonably possible that changes in the and Disclosures (ASC 820), which allows as a practical expedient, for the estimation of the fair values of investment securities will occur in the near term and that such changes could materially value of investments in investment companies for which the investment does not have a readily affect the amounts reported in the consolidated statement of financial position. determinable fair value, using net asset value per share or its equivalent, as reported by the LLS’s principal source of revenue is amounts contributed by the general public. Accordingly, LLS’s investment managers. Most investments classified in Levels 2 and 3 consist of shares or units operations are impacted by individual contributions, which are impacted by general economic in investment funds as opposed to direct interests in the funds’ underlying holdings, which may conditions, employment levels and other factors over which LLS has little or no control. In addition, be marketable. Because the net asset value reported by each fund is used as a practical expedient five contributors provided support to the co-pay program in 2012.

35 notes to consolidated financial statements The Leukemia & Lymphoma Society, Inc. / June 30, 2012 (with comparative amounts as of and for the year ended June 30, 2011) to estimate the fair value of LLS’s interest therein, its classification in Level 2 or 3 is based 2. Legacies and Contributions Receivable on LLS’s ability to redeem its interest at or near June 30. If the interest can be redeemed in the near term, the investment is classified as Level 2. LLS’s legacies and contributions receivable at June 30, 2012 and 2011 consist of unconditional Contributions and Deferred Revenue promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Amounts are scheduled to be received Contributions are recorded as revenue, at their fair value, when received or promised as follows (in thousands): unconditionally. Contributions received with donor restrictions that limit their use are reported 2012 2011 as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time and/or fulfillment of a purpose restriction, temporarily restricted net assets Less than one year $ 3,766 $ 17,905 are reclassified to unrestricted net assets and reported in the consolidated statement of activities 1 to 5 years 2,300 2,710 as net assets released from restrictions. Conditional contributions are recognized as revenue After 5 years 712 104 when the conditions have been substantially met. Subtotal 6,778 20,719 Deferred revenue includes amounts received for special events that will be held subsequent Less allowance for uncollectible accounts (778) (738) to the fiscal year end. Less discount to present value (1.5% to 5%) (587) (367) Donated Services Total $ 5,413 $ 19,614 LLS has determined that certain of the donated services it receives meet the criteria for recognition in the consolidated financial statements. Specifically, the donated services of family support group facilitators and research grant reviewers in the amount of $5,328,000 in 2012 and $5,983,000 Approximately 66% of LLS’s legacies and contributions receivable was from one estate in 2011 have been valued and are reported as both revenue and expense. at June 30, 2011, which was received in 2012. Cash Equivalents Cash equivalents consist of short term investments with an original maturity of three months 3. Investments or less from date of purchase, except for amounts held for long term purposes reported as investments. The following tables present LLS’s fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2012 and 2011 (in thousands): Investments Investments are stated at fair value. Investments in equity securities and mutual funds are 2012 Level 1 Level 2 Level 3 determined by utilizing quoted year end closing prices. Alternative investments are stated at net asset values provided by the fund managers or general partners based upon the underlying net Money market funds and cash $ 956 $ 956 $ – $ – assets of the funds consistent with the concepts of ASC 820. These values are reviewed and Fixed income (mutual funds): evaluated by management. Long duration 70,220 70,220 – – Fixed Assets and Depreciation Short duration 37,159 37,159 – – Fixed assets, which consist principally of equipment, software, and leasehold improvements, Other 1,061 1,061 – – are recorded at cost, if purchased, or at fair value at date of donation, if contributed, and Equities and other mutual funds: are depreciated or amortized using the straight-line method over the estimated useful lives Large cap 11,484 11,484 – – of the assets or the terms of the leases, if shorter. International 15,958 15,958 – – Professional Fees Small/mid cap 4,491 4,491 – – Professional fees included in the consolidated financial statements principally include fund Alternative investments: raising counsel fees, data processing services, contracted software development, and legal Funds of hedge funds 37,501 – 34,459 3,042 and auditing fees. Limited partnership  equity indices 5,254 – 5,254 –

Recently Issued Accounting Standards $ 184,084 $ 141,329 $ 39,713 $ 3,042 In May 2011, the FASB issued ASU 2011-04, Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. The new standards do not extend the use of fair value but, rather, provide guidance about how fair value should be applied where it already is required or permitted under IFRS or U.S. GAAP. For U.S. GAAP, most of the changes are clarifications of existing guidance or wording changes to align with IFRS. A nonpublic entity is required to apply the ASU prospectively for annual periods beginning after December 15, 2011. LLS expects that the adoption of ASU 2011-04 will not have a material impact on its consolidated financial statements.

36 2011 Level 1 Level 2 Level 3 The following table presents a reconciliation for all Level 3 assets measured at fair value Money market funds and cash $ 839 $ 839 $ – $ – as of June 30, 2012 and 2011 (in thousands):

Fixed income (mutual funds): Level 3 Assets Long duration 57,910 57,910 – – 2012 2011 Short duration 42,826 42,826 – – Balance at July 1 $ – $ 15,992 Other 1,039 1,039 – – Purchases 3,135 – Equities and other mutual funds: Investment expense – (211) Large cap 16,703 16,703 – – Net (decrease) increase in fair value International 6,552 6,552 – – Transfers to Level 2 due to expiration (93) 1,118 Small/mid cap 5,369 5,369 – – of lock-up period) – (16,899) Alternative investments: Balance at June 30 $ 3,042 $ –

Funds of hedge funds 35,503 – 35,503 – Limited partnership  equity indices 15,135 – 15,135 – 4. Awards and Grants $181,876 $131,238 $ 50,638 $ –

Awards and grants for research are recognized as expense when approved by LLS’s Board of Directors and conditions have been satisfied. Multiyear grants, which are generally two to five years Investment expenses of $625,000 and $752,000 have been netted against interest and dividend in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board income for the years ended June 30, 2012 and 2011, respectively. The unrealized (losses) and of Directors. LLS has unconditional grants payable of $68,315,000 and $66,098,000 at June 30, 2012 gains were ($5,514,000) and $7,428,000 for the years ended June 30, 2012 and 2011, respectively. and 2011, respectively. LLS invests in certain alternative investments, through “funds of hedge funds” investments, In addition, LLS has grant commitments of $48,875,000 and $63,500,000 at June 30, 2012 and 2011, which invest in multiple strategies through a portfolio of hedge fund managers to provide respectively, that are conditioned upon future events and, accordingly, are not recorded. diversification and reduce manager risk. These strategies create indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. 5. Co-Pay Assistance Program Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS’s risk with respect to such transactions is limited to its capital The Co-Pay Assistance program offers assistance to patients in meeting their insurance co-pay balance in each investment. obligations for prescription medications and/or private/public health insurance premiums. Amounts The underlying holdings of the limited partnership equity indices are principally domestic and awarded under the program are expensed in the year approved based on the available funding international marketable securities. in the program. Approximately $5,651,000 and $3,931,000 were included in the grants payable LLS’s alternative investments contain various redemption restrictions with required written notice balances for amounts awarded but unpaid at June 30, 2012 and 2011, respectively. ranging from 70 to 95 days, after the initial holding period. As of June 30, 2012, the following table summarizes the composition of such investments at fair value by the various redemption 6. Therapy Acceleration Program (TAP) provisions (in thousands):

Funds of Limited TAP is LLS’s strategic initiative to speed the development of blood cancer treatments and supportive Redemption period hedge funds partnerships diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug-enabling studies and clinical-stage projects. Monthly $ – $ 5,254 TAP contract commitments are recognized as an expense in the year program milestones are Quarterly 34,459 – achieved. Approximately $1,550,000 was included in the grants payable balances for milestones Annual 3,042 – achieved but unpaid at June 30, 2011. No amounts were payable at June 30, 2012. Multiyear Total $ 37,501 $ 5,254 contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS’s Board of Directors. As of June 30, 2012 and 2011, LLS has no unfunded commitments on its alternative investments. In addition, LLS has contract commitments of $19,078,000 and $25,169,000 at June 30, 2012 and 2011, respectively, that are conditioned upon future events and, accordingly, are not recorded.

37 notes to consolidated financial statements The Leukemia & Lymphoma Society, Inc. / June 30, 2012 (with comparative amounts as of and for the year ended June 30, 2011)

7. Pension Plan LLS follows the provisions of the New York Prudent Management of Institutional Funds Act (NYPMIFA), which imposes guidelines on the management and investment of endowment funds. LLS has a defined contribution 403(b) pension plan covering all employees meeting age and service LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate requirements. Contributions are based on a percentage of each eligible employee’s salary and so much of an endowment fund as LLS determines is prudent considering the uses, benefits, years of service. Expenses under this plan aggregated $3,967,000 and $3,823,000 for the years purposes and duration for which the endowment fund is established, subject to the intent of the ended June 30, 2012 and 2011, respectively. donor as expressed in the gift instrument. LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported LLS has a 457(b) deferred compensation plan (the 457 Plan) for its executive staff. The 457 Plan by its endowment funds while seeking to protect the original value of the gift. Under this policy, is a nonqualified deferred compensation plan subject to the provisions of the Internal Revenue the endowment assets are invested in a manner that is intended to produce results consistent with Code Section 457. Expenses under the 457 Plan approximated $157,000 and $167,000 for LLS’s overall investment strategy. the years ended June 30, 2012 and 2011, respectively. The assets and liabilities of the 457 Plan are included in investments and accounts payable in the accompanying consolidated statement The following table presents changes in the donor-restricted endowment funds for the year ended of financial position and amounted to approximately $1,196,000 and $973,000 at June 30, 2012 June 30, 2012 (in thousands): and 2011, respectively. Temporarily Permanently Unrestricted restricted restricted Total Endowment net assets at July 1 $ – $ 3,280 $ 3,892 $ 7,172 8. Lease Commitments Investment income – 77 11 88 Net (depreciation) appreciation – (202) 64 (138) The leases for premises, which LLS’s Home Office and chapters occupy, expire on various dates through September 30, 2018 and provide for certain payments subject to escalation and periodic Contributions – – 257 257 rate increases relating to real estate taxes, operating expenses, and utilities. The Home Office Net assets redesignated by donor – – (867) (867) lease expires in March 2016. Endowment net assets at June 30 $ – $ 3,155 $ 3,357 $ 6,512

The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands): The following table presents changes in the donor-restricted endowment funds for the year ended June 30, 2011 (in thousands). Year ending June 30: Temporarily Permanently 2013 $ 7,840 Unrestricted restricted restricted Total 2014 6,593 Endowment net assets at July 1 $ 1,895 $ 362 $ 3,688 $ 5,945 2015 5,904 Investment income – 152 – 152 2016 4,059 Net appreciation – 760 127 887 2017 1,714 Contributions – 111 105 216 Thereafter 450 Net assets redesignated by donor – – (28) (28) Total $ 26,560 Reclassification upon enactment of NYPMIFA (1,895) 1,895 – – 9. Temporarily and Permanently Restricted Net Assets Endowment net assets at June 30 $ – $ 3,280 $ 3,892 $ 7,172

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2012 and 2011 (in thousands): 10. Joint Costs Allocation

2012 2011 For the years ended June 30, 2012 and 2011, LLS incurred joint costs for informational materials Temporarily Permanently Temporarily Permanently and activities that included fund raising appeals as follows (in thousands): restricted restricted restricted restricted Time restrictions $ 1,150 $ – $ 15,259 $ – 2012 2011 Research 7,898 3,139 5,450 3,016 Fund raising $ 11,509 $ 12,543 Patient service 2,718 – 3,608 730 Patient and community service 1,049 1,078 Other 397 218 88 146 Public health education 9,522 10,725 Total $ 12,163 $ 3,357 $ 24,405 $ 3,892 Total $ 22,080 $ 24,346

38 national leaders senior staff

Chairman of the Board Pamela J. Haylock John E. Walter Lisa Stockmon Scott Carroll Association of Vascular Access President & Chief Executive Officer Senior Vice President Jackson Lewis Herriman, UT Marketing & Communications Louis DeGennaro, PhD Cincinnati, OH Raanan Horowitz Executive Vice President David Timko Vice Chair Elbit Systems of America, LLC Chief Mission Officer Senior Vice President Timothy Durst Fort Worth, TX Research & Scientific Programs Volunteer Engagement Baker Botts LLP Richard M. Jeanneret Dallas, TX George Omiros Mark Velleca, MD, PhD Ernst & Young, LLP Executive Vice President Chief Policy & Advocacy Officer Secretary/Treasurer New York, NY Chief Campaign & Steven L. Hooker Richard Winneker Armand Keating, MD Field Development Officer Portland, OR Senior Vice President Princess Margaret Hospital Research Toronto, Ontario, Canada Jeff Como Joseph B. Kelley Chief Information Officer Board of Directors Lilly USA, LLC Washington, DC Hildy Dillon The Leukemia & Lymphoma Senior Vice President Society of Canada Marie McDemmond Patient Services Pompano Beach, FL James A. Beck Philip Kozlowski Rodman N. Myers Nancy Allen Hefren-Tillotson, Inc. Senior Vice President Honigman Miller Schwartz President Butler, PA Human Resources and Cohn Canadian Operations William G. Behnke Detroit, MI Jimmy Nangle The Behnke Group Chief Financial Officer San Antonio, TX Derek M. Raghavan, MD, PhD, FACP Carolinas HealthCare System Jorge L. Benitez Michael Osso Charlotte, NC Accenture Senior Vice President Coral Gables, FL Steven T. Rosen, MD, FACP Major Gifts Robert H. Lurie Comprehensive Peter Bennett Brock Cancer Care Brock Development Corp. Chicago, IL Palm Beach Gardens, FL Kenneth M. Schwartz A. Dana Callow, Jr. Ernst & Young, LLP Boston Millennia Partners New York, NY Boston, MA Jay L. Silver Elizabeth Clark, PhD, MPH, ACSW Sugar Land, TX National Association of Social Workers Kathryn C. Vecellio Washington, DC Palm Beach, FL Jorge Cortes, MD Louise G. Warner The University of Texas Chagrin Falls, OH M.D. Anderson Cancer Center Matthew E. Winter Houston, TX Allstate Auto, Home & Agencies James H. Davis, PhD, JD Northbrook, IL Human Genome Sciences, Inc. Columbia, MD Bernard H. Garil Delray Beach, FL D. Gary Gilliland, MD Merck North Wales, PA

39 offices

Alabama Delaware Kentucky New Jersey Pennsylvania Washington D.C. 100 Chase Park South n Suite 220 100 West 10th Street n Suite 209 301 East Main Street n Suite 100 14 Commerce Drive n Suite 301 555 North Lane n Suite 5010 5845 Richmond Highway n Suite 800 Birmingham, AL 35244 Wilmington, DE 19801 Louisville, KY 40202-1077 Cranford, NJ 07016 Conshohocken, PA 19428 Alexandria, VA 22303 205.989.0098 302.661.7300 502.584.8490 908.956.6600 610.238.0360 703.399.2900

Alaska Florida Louisiana New Mexico 2405 Park Drive n Suite 100 West Virginia Harrisburg, PA 17110 3851 Piper Street n Suite U-331 2 Oakwood Boulevard n Suite 200 3636 South 1-10 Service Road 4600-A Montgomery Boulevard NE See Pittsburgh, PA Anchorage, AK 99508 Hollywood, FL 33020 Suite 304 Suite 201 717.652.6520

907.677.7980 954.744.5300 Metairie, LA 70001 Albuquerque, NM 87109 333 East Carson Street n Suite 441 Wisconsin 504.837.0945 505.872.0141 Pittsburgh, PA 15219 200 South Executive Drive n Suite 203 n Suite 101 Arizona 3319 Maguire Boulevard Brookfield, WI 53005 Orlando, FL 32803 412.395.2873 3877 North 7th Street n Suite 300 Maine New York 262.790.4701 407.898.0733 Phoenix, AZ 85014 See Massachusetts 5 Computer Drive West n Suite 100 Rhode Island 602.567.7600 4360 Northlake Boulevard n Suite 109 Albany, NY 12205 1210 Pontiac Avenue Wyoming Palm Beach Gardens, FL 33410 Maryland 518.438.3583 Cranston, RI 02920 See Colorado Arkansas 561.775.9954 100 Painters Mill Road n Suite 800 401.943.8888 4053 Maple Road n Suite 110 See Missouri Owings Mills, MD 21117 n Amherst, NY 14226 3507 East Frontage Road Suite 300 443.471.1600 South Carolina Tampa, FL 33607 716.834.2578 California 107 Westpark Boulevard n Suite 150 Puerto Rico 813.963.6461 340 West Fallbrook Avenue Massachusetts 1324 Motor Parkway n Suite 102 Columbia, SC 29210 Suite 101 9 Erie Drive n Suite 101 Hauppauge, NY 11749 Georgia 803.731.4060 Fresno, CA 93711 Natick, MA 01760 631.370.7530 559.435.1482 3715 Northside Parkway 508.810.1300 South Dakota Commercial 18 Building 400 Northcreek n Suite 300 475 Park Avenue South n 8th Floor 800 RH Todd Avenue n Suite 205 6033 West Century Boulevard See Minnesota Atlanta, GA 30327 Michigan New York, NY 10016 San Juan, PR 00907 Suite 300 404.720.7900 1471 East Twelve Mile Road 212.376.7100 Tennessee 787.725.2200 Los Angeles, CA 90045 Building H n 310.342.5800 Hawaii 1311 Mamaroneck Avenue n Suite 130 404 BNA Drive Suite 102 Madison Heights, MI 48071 White Plains, NY 10605 Nashville, TN 37217 30 Aulike Street n Suite 406 765 The City Drive South n Suite 260 248.581.3900 615.331.2980 Kailua, HI 96734 914.949.0084 Orange, CA 92868 Canada 714.481.5600 808.261.3020 Minnesota North Carolina Texas n 8441 Wayzata Boulevard Suite 340 401 Harrison Oaks Boulevard 8111 LBJ Freeway n Suite 425 2143 Hurley Way n Suite 110 Idaho Golden Valley, MN 55426 Suite 200 Dallas, TX 75251 Sacramento, CA 95825 2404 West Bank Drive n Suite 103 763.852.3000 Cary, NC 27513 972.996.5900 Canada Corporate 916.929.4720 Boise, ID 83705 919.367.4100 804-2 Lansing Square 208.658.6662 Mississippi 5433 Westheimer n Suite 300 9150 Chesapeake Drive n Suite 100 Toronto, ON M2J 4P8 n Houston, TX 77056 San Diego, CA 92123 408 Fontaine Place Suite 104 North Dakota 416.661.9541 x104 Illinois 713.680.8088 858.427.6648 Ridgeland, MS 39157 See Minnesota 651 West Washington Boulevard 601.956.7447 Atlantic Canada Region 431 Isom Road n Suite 125 n Suite 1650 Suite 400 n 221 Main Street Ohio San Antonio, TX 78216 1660 Hollis Street HS2 San Francisco, CA 94105 Chicago, IL 60661 Missouri Halifax, NS B3J 1V7 2300 Wall Street n Suite H 210.998.5400 312.651.7350 n 415.625.1100 77 West Port Plaza Suite 480 Cincinnati, OH 45212 902.422.5999 St. Louis, MO 63146-3111 675 North First Street n Suite 1100 Indiana 513.698.2828 Utah BC/Yukon Region 314.878.0780 n San Jose, CA 95112-5156 n 5296 Commerce Drive Suite 101 n 941 East 86th Street Suite 100 n Suite E 1682 West 7th Avenue Suite 310 2225 City Gate Drive Murray, UT 84107 408.490.2666 Indianapolis, IN 46240 Montana Columbus, OH 43219 Vancouver, BC V6J 4S6 801.281.6618 317.860.3840 614.476.7194 604.733.2873 1525 State Street n Suite 205 See Oregon

Santa Barbara, CA 93101 n Vermont Ontario Region Iowa Nebraska 5700 Brecksville Road 3rd Floor 805.884.1883 8033 University Boulevard n Suite A Independence, OH 44131 See Albany, NY 1502-480 University Avenue 10832 Old Mill Road n Suite 200 216.264.5722 Toronto, ON M5G 1V2 Des Moines, IA 50325 Omaha, NE 68154 Colorado Virginia 416.585.2873 515.270.6169 402.344.2242 720 South Colorado Boulevard Oklahoma 5540 Falmouth Street n Suite 101 Prairies Region Suite 500-S Kansas 500 North Broadway n Suite 250 Richmond, VA 23230 Nevada 2020 10th Street NW Denver, CO 80246 6811 Shawnee Mission Parkway Oklahoma City, OK 73102 804.673.5690 720.440.8620 6280 South Valley View Boulevard Calgary, AB T2M 3M2 Cloverleaf Building #1 n Suite 202 405.953.8888 Suite 342 Washington 403.263.5300 Shawnee Mission, KS 66202-4001 Las Vegas, NV 89118 Connecticut n 913.262.1515 Oregon 123 36th Street Suite 100 Région de Québec n 702.436.4220 372 Danbury Road Suite 200 Seattle, WA 98109 9320 SW Barbur Boulevard 705-1255 University Street Wilton, CT 06897 300 North Main n Suite 300 New Hampshire Suite 140 206.628.0777 Montreal, QC H3B 3W1 203.665.1400 Wichita, KS 67202 Portland, OR 97219 See Massachusetts 514.875.1000 316.266.4050 503.245.9866

40 1 2 3 4 5

8 9 the

6 7 14 15 16 faces 10 11 12 13 18 19 17 of 20 21 22 23 24 today

1. Sophie Medlock, leukemia survivor, 7. Arthur Valentine, non-Hodgkin 13. Billie, ALL survivor, Boulder, CO 19. Jamie Quevedo & Joshua, PH+ ALL - Post Falls, ID lymphoma survivor, Narbeth, PA Jamie passed away a year after giving birth 14. Brianna Garcia, ALL survivor, to her son Joshua. West Palm Beach, FL 2. Isaac Bailey Duck, lymphoma survivor, 8. Judie Orem, CML survivor, Orange, CA Springfield, VA Manassas, VA 20. Douglas McBride, MALT lymphoma 9. Madalyn McCarthy, ALL survivor, 15. Virginia Garner, CML survivor, survivor 3. Melissa Casteel, Hodgkin lymphoma Chicago, IL Claremont, CA survivor, Massachusetts 21. Agnes Connors, B-cell lymphoma 10. Kimie Kiyomi Metcalf, ALL survivor, 16. Alex Wilkison, leukemia survivor, survivor 4. Anthony Poichetti, juvenile Chino, CA California myelomonocytic leukemia survivor, 22. James DeMasi, non-Hodgkin lymphoma Mount Washington, KY 11. Karina Miziolek, leukemia survivor, 17. Victoria Callihan, ALL survivor, survivor, Philadelphia, PA Portland, OR McLean, VA 5. Jonte Smith, ALL & Sicklecell survivor, 23. Jeff Gusinow, follicular lymphoma Kansas City, MO 12. Jacob Kenneth DeLong, ALL survivor, 18. Angela Mary Butler, Hodgkin survivor, Eugene, OR Santa Clarita, CA lymphoma survivor, St. John’s 6. Sadie Floyd, ALL survivor, Newfoundland, Canada 24. Aaron Baral, T-cell ALL survivor, Portland, OR Boston, MA Sophie Medlock, Leukemia Survivor cure leukemia, lymphoma, hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. not in the future, but now. not in the future, but now.

1311 Mamaroneck Avenue Suite 310 White Plains, NY 10605 914.949.5213 www.lls.org

P001 20M 12/12